CUMULATIVE SUPPLEMENT 2
FEBRUARY 2016



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

36th EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

36th EDITION

Cumulative Supplement 2

February 2016

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

36th EDITION

CUMULATIVE SUPPLEMENT 2
February 2016

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BD RX INC (BD RX)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
CITRON PHARMA LLC (CITRON PHARMA LLC)	CASPER PHARMA LLC (CASPER PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate

for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBVIE	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active

ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts,

esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2015	MAR 2016	JUN 2016	SEPT 2016	DEC 2016
DRUG PRODUCTS LISTED	17151				
SINGLE SOURCE	2664 (15.5%)				
MULTISOURCE	14487 (84.5%)				
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)				
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)				
EXCEPTIONS[1]	73 (0.4%)				
NEW MOLECULAR ENTITIES APPROVED	28				
NUMBER OF APPLICANTS	1011				

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will

display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

>D>			CAMPRAL					
>D>	AB	+	FOREST LABS	333MG	N021431	001	Jul 29, 2004	Feb DISC
>A>		@		333MG	N021431	001	Jul 29, 2004	Feb DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

		@	INGENUS PHARMS NJ	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Jan CAHN
		@	SUN PHARM INDS	325MG;50MG;40MG	A040601	001	Jul 29, 2005	Jan CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

>A>	AA		ALVOGEN MALTA	325MG;5MG	A202677	003	Mar 08, 2016	Feb NEWA
	AA			325MG;7.5MG	A202677	001	Jul 26, 2012	Jan CAHN
	AA			325MG;10MG	A202677	002	Jul 26, 2012	Jan CAHN
>D>	AA		COASTAL PHARMS	325MG;2.5MG	A090177	001	Oct 20, 2008	Feb CAHN
>D>	AA			325MG;5MG	A090177	002	Oct 20, 2008	Feb CAHN
>D>	AA			325MG;7.5MG	A090177	003	Oct 20, 2008	Feb CAHN
>D>	AA			325MG;10MG	A090177	004	Oct 20, 2008	Feb CAHN
>D>		@		500MG;7.5MG	A090177	005	Oct 20, 2008	Feb CAHN
>D>		@		650MG;10MG	A090177	006	Oct 20, 2008	Feb CAHN
>A>	AA		MAYNE PHARMA INC	325MG;2.5MG	A090177	001	Oct 20, 2008	Feb CAHN
>A>	AA			325MG;5MG	A090177	002	Oct 20, 2008	Feb CAHN
>A>	AA			325MG;7.5MG	A090177	003	Oct 20, 2008	Feb CAHN
>A>	AA			325MG;10MG	A090177	004	Oct 20, 2008	Feb CAHN
>A>		@		500MG;7.5MG	A090177	005	Oct 20, 2008	Feb CAHN
>A>		@		650MG;10MG	A090177	006	Oct 20, 2008	Feb CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

>A>	AP		AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016	Feb NEWA

TABLET, EFFERVESCENT;ORAL

CETYLEV

			ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Jan NEWA
		+		2.5GM	N207916	002	Jan 29, 2016	Jan NEWA

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

>D>	AB		RANBAXY	200MG	A074975	001	Sep 30, 1998	Feb DISC
>A>		@		200MG	A074975	001	Sep 30, 1998	Feb DISC

TABLET;BUCCAL

SITAVIG

		+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jan CAHN

TABLET;ORAL

ACYCLOVIR

>D>	AB		SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Feb DISC
>A>		@		400MG	A074980	001	Sep 30, 1998	Feb DISC
>D>	AB			800MG	A074980	002	Sep 30, 1998	Feb DISC
>A>		@		800MG	A074980	002	Sep 30, 1998	Feb DISC

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

>D>		+	HIKMA MAPLE	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997	Feb DISC
>A>		@		EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997	Feb DISC
>D>				EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997	Feb DISC
>A>		@		EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997	Feb DISC

ACYCLOVIR SODIUM

>D>	AP		BEDFORD	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Feb DISC
>A>		@		EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Feb DISC
>D>		+		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb CTEC
>A>		@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb DISC
>A>	AP	+		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb CTEC
>A>	AP		HIKMA PHARMS LLC	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Feb NEWA
>A>		+		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb CRLD

INJECTABLE;INJECTION
ACYCLOVIR SODIUM

>A>	AP		EQ 1GM BASE/VIAL		A205771	002	Feb 29, 2016	Feb NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
ALFUZOSIN HYDROCHLORIDE

	AB		UNICHEM LABS LTD	10MG		A203192	001	Jan 28, 2016	Jan NEWA

ALLOPURINOL

TABLET;ORAL
ZYLOPRIM

	AB		SEBELA IRELAND LTD	100MG		N016084	001		Jan CAHN
	AB	+		300MG		N016084	002		Jan CAHN

ALMOTRIPTAN MALATE

TABLET;ORAL
ALMOTRIPTAN MALATE

>A>	AB		AJANTA PHARMA LTD	EQ 6.25MG BASE		A205523	001	Mar 03, 2016	Feb NEWA
>A>	AB			EQ 12.5MG BASE		A205523	002	Mar 03, 2016	Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET;ORAL
LOTRONEX

>D>	AB		PROMETHEUS LABS	EQ 0.5MG BASE		N021107	002	Dec 23, 2003	Feb CAHN
>D>	AB	+		EQ 1MG BASE		N021107	001	Feb 09, 2000	Feb CAHN
>A>	AB		SEBELA IRELAND LTD	EQ 0.5MG BASE		N021107	002	Dec 23, 2003	Feb CAHN
>A>	AB	+		EQ 1MG BASE		N021107	001	Feb 09, 2000	Feb CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

		@	ACTAVIS LABS FL INC	0.5MG		A077198	001	May 13, 2010	Jan DISC
		@		1MG		A077198	002	May 13, 2010	Jan DISC
		@		2MG		A077198	003	May 13, 2010	Jan DISC
		@		3MG		A077198	004	May 13, 2010	Jan DISC
		@	IMPAX LABS	0.5MG		A077968	004	May 24, 2007	Jan DISC
		@		1MG		A077968	003	May 24, 2007	Jan DISC
		@		2MG		A077968	002	May 24, 2007	Jan DISC
		@		3MG		A077968	001	May 24, 2007	Jan DISC

ALPROSTADIL

SUPPOSITORY;URETHRAL
MUSE

		+	MEDA PHARMS	0.125MG		N020700	001	Nov 19, 1996	Jan CRLD
		+		0.25MG		N020700	002	Nov 19, 1996	Jan CRLD
		+		0.5MG		N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL
AMANTADINE HYDROCHLORIDE

	AB		BIONPHARMA INC	100MG		A078720	001	May 29, 2008	Jan CAHN

AMLODIPINE BESYLATE

TABLET;ORAL
AMLODIPINE BESYLATE

>D>	AB		ASCENT PHARMS INC	EQ 2.5MG BASE		A206367	001	Dec 10, 2015	Feb CAHN
>D>	AB			EQ 5MG BASE		A206367	002	Dec 10, 2015	Feb CAHN
>D>	AB			EQ 10MG BASE		A206367	003	Dec 10, 2015	Feb CAHN
>A>	AB		INVAGEN PHARMS	EQ 2.5MG BASE		A206367	001	Dec 10, 2015	Feb CAHN
>A>	AB			EQ 5MG BASE		A206367	002	Dec 10, 2015	Feb CAHN
>A>	AB			EQ 10MG BASE		A206367	003	Dec 10, 2015	Feb CAHN

AMMONIA N-13

INJECTABLE;INTRAVENOUS
AMMONIA N 13

	AP		MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A207025	001	Feb 03, 2016	Jan NEWA
	AP		MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A204457	001	Nov 18, 2015	Jan NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

>D>	AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Feb DISC
>A>		@	250MG	A065016	001	Apr 08, 1999	Feb DISC
>D>	AB		500MG	A065016	002	Apr 08, 1999	Feb DISC
>A>		@	500MG	A065016	002	Apr 08, 1999	Feb DISC

TABLET;ORAL

AMOXICILLIN

>D>	AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Feb DISC
>A>		@	500MG	A065059	001	Nov 24, 2000	Feb DISC
>D>	AB		875MG	A065059	002	Nov 24, 2000	Feb DISC
>A>		@	875MG	A065059	002	Nov 24, 2000	Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN

>D>	AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Feb DISC
>A>		@	125MG	A065021	001	Dec 23, 1999	Feb DISC
>D>	AB		250MG	A065021	002	Dec 23, 1999	Feb DISC
>A>		@	250MG	A065021	002	Dec 23, 1999	Feb DISC

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

+		VERNALIS R AND D LTD	775MG	N050813	001	Jan 23, 2008	Jan CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>	AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb CDFR
>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb CDFR
>A>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb CDFR
>D>	AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb DISC
>A>		@	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb DISC
>D>	AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb DISC
>A>		@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb DISC
>D>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb DISC
>A>		@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb DISC

SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb CDFR
>D>	AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb CDFR
>D>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb CDFR

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	SUN PHARM INDS LTD	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Feb DISC
>A>		@	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb DISC
>A>		@	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb DISC
>D>	AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb DISC
>A>		@	400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb DISC

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan NEWA
	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan NEWA
	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan NEWA
	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan NEWA
	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan NEWA
	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

>D>	AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb CTNA
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb CTNA
>D>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
>D>	AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb CTNA
>D>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

CAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB		IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb	NEWA
>A>	AB			2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb	NEWA
>A>	AB			3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb	NEWA
>A>	AB			5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb	NEWA
>A>	AB			6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb	NEWA
>A>	AB			7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb	NEWA
>A>	AB		TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb	CTNA
>A>	AB			2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb	CTNA
>A>	AB			3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb	CTNA
>A>	AB			5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb	CTNA
>A>	AB			6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb	CTNA
>A>	AB			7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb	CTNA

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	AB		ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan	NEWA
	AB			1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan	NEWA
	AB			2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan	NEWA
	AB			3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan	NEWA
	AB			3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan	NEWA
	AB			5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan	NEWA
	AB			7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan	NEWA

ARIPIPRAZOLE

SOLUTION;ORAL
ARIPIPRAZOLE

>D>	AA		AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb	CRLD
>A>	AA	+		1MG/ML	A203906	001	Aug 14, 2015	Feb	CRLD

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION
M.V.I.-12 LYOPHILIZED

		@	TELIGENT PHARMA INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jan	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

		@	NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007	Jan	CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL
CARISOPRODOL AND ASPIRIN

	AB		INGENUS PHARMS NJ	325MG;200MG	A040832	001	Jan 07, 2010	Jan	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

		@	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jan	CAHN
		+	SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jan	CRLD

SOMA COMPOUND W/ CODEINE

		@	MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983	Jan	DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL
ASPIRIN AND DIPYRIDAMOLE

>A>	AB		AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016	Feb	NEWA

ATENOLOL

TABLET;ORAL
ATENOLOL

	AB		ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan	CAHN
	AB			50MG	A072303	001	Jul 15, 1988	Jan	CAHN
	AB			100MG	A072304	001	Jul 15, 1988	Jan	CAHN

TENORMIN

	AB		ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990	Jan	CAHN
	AB			50MG	N018240	001		Jan	CAHN
	AB	+		100MG	N018240	002		Jan	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan CAHN
AB			100MG;25MG	A072302	001	May 31, 1990	Jan CAHN

TENORETIC 100

AB	+	ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan CAHN

TENORETIC 50

AB		ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan CAHN

AURANOFIN

CAPSULE;ORAL

RIDAURA

	+	SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985	Jan CAHN

AZATHIOPRINE

TABLET;ORAL

IMURAN

	@	SEBELA IRELAND LTD	25MG	N016324	002		Jan CAHN
AB	+		50MG	N016324	001		Jan CAHN

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

	@	SEBELA IRELAND LTD	EQ 100MG BASE/VIAL	N017391	001		Jan CAHN

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

		ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jan CAHN
	+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jan CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

		ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Jan CAHN
	+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Jan CAHN

BACLOFEN

TABLET;ORAL

BACLOFEN

AB		NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009	Jan NEWA

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

	+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan NEWA

SUSPENSION;ORAL

READI-CAT 2

	+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan NEWA

READI-CAT 2 SMOOTHIES

		BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan DISC
	@		10MG	A076267	002	Feb 11, 2004	Jan DISC
	@		20MG	A076267	003	Feb 11, 2004	Jan DISC
	@		40MG	A076267	004	Feb 11, 2004	Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	ACTAVIS LABS FL INC	5MG;6.25MG	A076342	001	Feb 11, 2004	Jan DISC
	@		10MG;12.5MG	A076342	002	Feb 11, 2004	Jan DISC
	@		20MG;12.5MG	A076342	003	Feb 11, 2004	Jan DISC
	@		20MG;25MG	A076342	004	Feb 11, 2004	Jan DISC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA			200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

BENZAMYCIN PAK

>A>	+	CUTANEA	5%;3%	N050769	001	Nov 27, 2000	Feb CAHN
>D>	+	VALEANT LUXEMBOURG	5%;3%	N050769	001	Nov 27, 2000	Feb CAHN

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL

>A> SERNIVO

>A>	+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb NEWA

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

	@	SEBELA IRELAND LTD	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG	N050719	001	Aug 15, 1996	Jan CAHN

>A> BRIVARACETAM

>A> SOLUTION;INTRAVENOUS

>A> BRIVIACT

>A>	+	UBC INC	50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	Feb NEWA

>A> SOLUTION;ORAL

>A> BRIVIACT

>A>	+	UCB INC	10MG/ML	N205838	001	Feb 18, 2016	Feb NEWA

>A> TABLET;ORAL

>A> BRIVIACT

>A>		UCB INC	10MG	N205836	001	Feb 18, 2016	Feb NEWA
>A>			25MG	N205836	002	Feb 18, 2016	Feb NEWA
>A>			50MG	N205836	003	Feb 18, 2016	Feb NEWA
>A>			75MG	N205836	004	Feb 18, 2016	Feb NEWA
>A>	+		100MG	N205836	005	Feb 18, 2016	Feb NEWA

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB	+	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan CRLD

PARLODEL

	@	US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982	Jan DISC

TABLET;ORAL

BROMOCRIPTINE MESYLATE

>D> AB		LEK PHARMS	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb CAHN
AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan CRLD
>A> AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb CAHN

PARLODEL

	@	US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Jan DISC

BUDESONIDE

CAPSULE;ORAL

ENTOCORT EC

AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan CAHN

SUSPENSION;INHALATION

BUDESONIDE

>A> AN		TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb NEWA

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan	NEWA
AB		EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan	NEWA
AB1		150MG	A206674	002	Feb 09, 2016	Jan	NEWA
AB1		200MG	A206674	003	Feb 09, 2016	Jan	NEWA
>A> AB1	SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb	NEWA
>A> AB1		150MG	A205794	002	Mar 01, 2016	Feb	NEWA
>A> AB1		200MG	A205794	003	Mar 01, 2016	Feb	NEWA

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

@	CLARIS	2MG/ML	A075697	001	Oct 23, 2001	Jan	CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

+	HORIZON PHARMA	100MG;2MG	A086557	001	Oct 04, 1983	Jan	CAHN

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB	BIONPHARMA INC	0.25MCG	A091174	001	May 24, 2013	Jan	CAHN
AB		0.5MCG	A091174	002	May 24, 2013	Jan	CAHN

INJECTABLE;INJECTION

CALCITRIOL

>D> AP	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Feb	CTEC
>A>		0.001MG/ML	A078066	001	Jan 29, 2008	Feb	CTEC
>D> AP	ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003	Feb	DISC
>A> @		0.001MG/ML	A076206	001	Sep 17, 2003	Feb	DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

>D> AT	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	002		Feb	DISC
>A> @		25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	002		Feb	DISC

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

>D> AT	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	003		Feb	DISC
>A> @		25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	003		Feb	DISC

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

>D> AT	FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	007	Jun 24, 1988	Feb	DISC
>A> @		25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	007	Jun 24, 1988	Feb	DISC

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

>D> AT	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	001		Feb	DISC
>A> @		25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	001		Feb	DISC

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

>D> AT	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982	Feb	DISC
>A> @		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982	Feb	DISC

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

>D> AT	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982	Feb	DISC
>A> @		25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982	Feb	DISC

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

>D> AT	FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988	Feb	DISC
>A> @		25.7MG/100ML;3.5GM/100ML;5.08	N018379	008	Jun 24, 1988	Feb	DISC

		SOLUTION;INTRAPERITONEAL							
		DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
			MG/100ML;538MG/100ML;448MG/100ML						
		DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
>D>	AT	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982	Feb DISC		
>A>		@	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982	Feb DISC		
		DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
>D>	AT	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985	Feb CTEC		
>A>			25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985	Feb CTEC		
		DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
>D>	AT	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Feb CTEC		
>A>			25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Feb CTEC		
		CAPTOPRIL							
		TABLET;ORAL							
		CAPTOPRIL							
		@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan DISC		
		@	25MG	A074363	002	Nov 09, 1995	Jan DISC		
		@	50MG	A074363	003	Nov 09, 1995	Jan DISC		
		@	100MG	A074363	004	Nov 09, 1995	Jan DISC		
		CARBAMAZEPINE							
		CAPSULE, EXTENDED RELEASE;ORAL							
		CARBAMAZEPINE							
	AB	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan CAHN		
	AB		200MG	A076697	002	May 20, 2011	Jan CAHN		
	AB		300MG	A076697	003	May 20, 2011	Jan CAHN		
		CARBIDOPA							
		TABLET;ORAL							
		CARBIDOPA							
>A>	AB	EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb NEWA		
		CARBOPLATIN							
		INJECTABLE;IV (INFUSION)							
		CARBOPLATIN							
>D>	AP	EBEWE PHARMA	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb CAHN		
>D>	AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb CAHN		
>D>	AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb CAHN		
>A>	AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb CAHN		
>A>	AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb CAHN		
>A>	AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb CAHN		
		CARFILZOMIB							
		POWDER;INTRAVENOUS							
		KYPROLIS							
>D>		+ ONYX PHARMS	60MG/VIAL	N202714	001	Jul 20, 2012	Feb CAHN		
>A>		+ ONYX THERAP	60MG/VIAL	N202714	001	Jul 20, 2012	Feb CAHN		
		CARISOPRODOL							
		TABLET;ORAL							
		CARISOPRODOL							
	AA	INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan CAHN		
		CEFADROXIL/CEFADROXIL HEMIHYDRATE							
		FOR SUSPENSION;ORAL							
		CEFADROXIL							
>D>		RANBAXY	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb DISC		
>A>		@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb DISC		
>D>	AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb DISC		
>A>		@	EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb DISC		
>D>	AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb DISC		
>A>		@	EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb DISC		

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

	AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

	AP		QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan NEWA
	AP			EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan NEWA
	AP			EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan NEWA

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CEFOTAXIME SODIUM

>A>	AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb NEWA
>A>	AP			EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb NEWA

CLAFORAN

	AP	+	US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan CAHN
	AP	+		EQ 1GM BASE/VIAL	N050547	002		Jan CAHN
	AP	+		EQ 2GM BASE/VIAL	N050547	003		Jan CAHN
	AP	+		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan CAHN

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

		+	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan CAHN
		+		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan CAHN

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		@	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan CAHN
		@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan CAHN

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

		@	TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan CAHN
>D>		@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
>A>	AP			EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
		@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan CAHN
		@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan CAHN
>D>		@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD
>A>	AP			EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD
		@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan CAHN
		@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

>D>	AB		SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb DISC
>A>		@		EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb DISC
>D>	AB			EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb DISC
>A>		@		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb DISC

TABLET;ORAL

CEFPODOXIME PROXETIL

>D>	AB		SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb DISC
>A>		@		EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb DISC
>D>	AB			EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb DISC
>A>		@		EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb DISC

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFTIN

>D>	AB		GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb CTEC
>A>				EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb CTEC
>D>	AB	+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb CTEC
>A>		+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb CTEC

CEFUROXIME AXETIL

>D>	AB		SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb DISC
>A>		@		EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb DISC
>D>	AB			EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb DISC
>A>		@		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb DISC

TABLET;ORAL

CEFUROXIME AXETIL

>D>	AB		SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb DISC

TABLET;ORAL
CEFUROXIME AXETIL

>A>		@	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb	DISC
>D>	AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb	DISC
>A>		@	EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb	DISC
>D>	AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb	DISC
>A>		@	EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb	DISC

CEFUROXIME SODIUM

INJECTABLE;INJECTION
ZINACEF

	AP	+ IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan	CAHN
	AP	+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan	CAHN

ZINACEF IN PLASTIC CONTAINER

		@ IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan	CAHN
		+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan	CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
ZINACEF

	AB	+ IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan	CAHN

CELECOXIB

CAPSULE;ORAL
CELECOXIB

	AB	AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan	NEWA
	AB		100MG	A206827	002	Feb 01, 2016	Jan	NEWA
	AB		200MG	A206827	003	Feb 01, 2016	Jan	NEWA
	AB		400MG	A206827	004	Feb 01, 2016	Jan	NEWA
>A>	AB	MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb	NEWA
>A>	AB		100MG	A204590	002	Mar 16, 2016	Feb	NEWA
>A>	AB		200MG	A204590	003	Mar 16, 2016	Feb	NEWA
>A>	AB		400MG	A204590	004	Mar 16, 2016	Feb	NEWA

CEPHALEXIN

CAPSULE;ORAL
CEPHALEXIN

>D>	AB	RANBAXY	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb	DISC
>A>		@ SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb	DISC
>D>	AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb	DISC
>A>		@	EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb	DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL
PERIOGARD

	AT	COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan	NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	AA	COASTAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Feb	CAHN
>A>	AA	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Feb	CAHN

CHLORTHALIDONE

TABLET;ORAL
CHLORTHALIDONE

	AB	MYLAN	25MG	A086831	002		Jan	CTEC
	AB	SUN PHARM INDS	25MG	A089286	002	Jul 21, 1986	Jan	NEWA

CHLORZOXAZONE

TABLET;ORAL
CHLORZOXAZONE

>A>		@ AUROLIFE PHARMA LLC	250MG	A089852	001	May 04, 1988	Feb	CAHN
>A>		@	500MG	A089853	001	May 04, 1988	Feb	CAHN
>D>		@ SANDOZ	250MG	A089852	001	May 04, 1988	Feb	CAHN
>D>		@	500MG	A089853	001	May 04, 1988	Feb	CAHN

CICLESONIDE

AEROSOL, METERED;INHALATION
ALVESCO

		+ TAKEDA GMBH	0.08MG/INH	N021658	002	Jan 10, 2008	Jan	CRLD

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

		@	ACTAVIS LABS FL INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010	Jan DISC
		@		425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010	Jan DISC

CLARITHROMYCIN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

>A>	AB		ALLIED PHARMA INC	500MG	A203243	001	Feb 29, 2016	Feb NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

VELTIN

	BX	+	AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010	Jan CAHN

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

ANAFRANIL

	AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan CRLD
	AB			50MG	N019906	002	Dec 29, 1989	Jan CRLD

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

>A>		@	AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988	Feb CAHN
>A>		@		0.2MG	A070886	001	Aug 31, 1988	Feb CAHN
>A>		@		0.3MG	A071294	001	Aug 31, 1988	Feb CAHN
>D>		@	SANDOZ	0.1MG	A070887	001	Aug 31, 1988	Feb CAHN
>D>		@		0.2MG	A070886	001	Aug 31, 1988	Feb CAHN
>D>		@		0.3MG	A071294	001	Aug 31, 1988	Feb CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

>A>		@	AUROLIFE PHARMA LLC	7.5MG	A072220	001	Aug 26, 1988	Feb CAHN
>A>		@		15MG	A072112	001	Aug 26, 1988	Feb CAHN
>D>		@	SANDOZ	7.5MG	A072220	001	Aug 26, 1988	Feb CAHN
>D>		@		15MG	A072112	001	Aug 26, 1988	Feb CAHN

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

>A>		@	AUROLIFE PHARMA LLC	15MG	A072514	001	May 11, 1990	Feb CAHN
>D>		@	SANDOZ	15MG	A072514	001	May 11, 1990	Feb CAHN

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

	AB		INGENUS PHARMS NJ	0.5MG;500MG	A040618	001	May 13, 2008	Jan CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

>A>		+	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001		Feb CAHN
>D>		+	PAR STERILE PRODUCTS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001		Feb CAHN

CORTICOTROPIN

INJECTABLE;INJECTION

PURIFIED CORTROPHIN GEL

>A>		@	ANI PHARMS	40 UNITS/ML	N008975	001		Feb CAHN
>A>		@		80 UNITS/ML	N008975	002		Feb CAHN
>D>		@	ORGANON USA INC	40 UNITS/ML	N008975	001		Feb CAHN
>D>		@		80 UNITS/ML	N008975	002		Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION

CORTROPHIN-ZINC

>A>		@	ANI PHARMS	40 UNITS/ML	N009854	001		Feb CAHN
>D>		@	ORGANON USA INC	40 UNITS/ML	N009854	001		Feb CAHN

CYANOCOBALAMIN

SPRAY, METERED;NASAL

NASCOBAL

>A>		+	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Feb CAHN
>D>		+	PAR PHARM	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Feb CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

	AA		INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Jan CAHN

DACTINOMYCIN

INJECTABLE;INJECTION

DACTINOMYCIN

>D>	AP		EUROHLTH INTL SARL	0.5MG/VIAL	A090304	001	Mar 16, 2010	Feb DISC
>A>		@		0.5MG/VIAL	A090304	001	Mar 16, 2010	Feb DISC

DALBAVANCIN HYDROCHLORIDE

POWDER;IV (INFUSION)

DALVANCE

		+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jan CDFR

DANTROLENE SODIUM

INJECTABLE;INJECTION

DANTROLENE SODIUM

>A>	AP		MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Feb NEWA

DAPSONE

GEL;TOPICAL

>A>			ACZONE					
>A>		+	ALLERGAN INC	7.5%	N207154	001	Feb 24, 2016	Feb NEWA

DAPTOMYCIN

POWDER;INTRAVENOUS

CUBICIN

	AP	+	CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Jan CDFR

DAPTOMYCIN

	AP		HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Jan CDFR

POWDER;IV (INFUSION)

CUBICIN

		@	CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003	Jan CDFR

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

ENABLEX

	AB		ALLERGAN PHARMS INTL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Jan CAHN
	AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Jan CAHN

DEFERASIROX

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

	AB		ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
	AB			250MG	A203560	002	Jan 26, 2016	Jan NEWA
	AB			500MG	A203560	003	Jan 26, 2016	Jan NEWA

EXJADE

	AB		NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
	AB			250MG	N021882	002	Nov 02, 2005	Jan CFTG
	AB	+		500MG	N021882	003	Nov 02, 2005	Jan CFTG

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

NORPRAMIN

	AB		US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan CAHN
	AB			25MG	N014399	001		Jan CAHN
	AB			50MG	N014399	003		Jan CAHN
	AB			75MG	N014399	004		Jan CAHN
	AB	+		100MG	N014399	005		Jan CAHN
	AB			150MG	N014399	006		Jan CAHN

DESONIDE

CREAM;TOPICAL

DESONIDE

	AB	G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan	CAHN

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

>A>	AB	TELIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb	NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

>A>	AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb	NEWA
>A>	AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb	NEWA

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB

	+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan	NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

	AP	ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan	NEWA

PRECEDEX

>D>		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb	CRLD
>A>		+	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb	CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb	CAHN
>A>	AB		5MG	A201231	002	Sep 24, 2015	Feb	CAHN
>A>	AB		10MG	A201231	003	Sep 24, 2015	Feb	CAHN
>D>	AB	SUN PHARM INDS LTD	2.5MG	A201231	001	Sep 24, 2015	Feb	CAHN
>D>	AB		5MG	A201231	002	Sep 24, 2015	Feb	CAHN
>D>	AB		10MG	A201231	003	Sep 24, 2015	Feb	CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

	AB	MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan	NEWA
	AB		10MG	A206735	002	Jan 27, 2016	Jan	NEWA
	AB		15MG	A206735	003	Jan 27, 2016	Jan	NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

>A>	AA	NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb	NEWA
>A>	AA		10MG	A204330	002	Mar 16, 2016	Feb	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DESTROMETHORPHAN HYDROBROMIDE

>D>		@ ANI PHARMS	15MG/5ML;6.25MG/5ML	N011265	002	Apr 02, 1984	Feb	CMS1

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>A>		@ ANI PHARMS	15MG/5ML;6.25MG/5ML	N011265	002	Apr 02, 1984	Feb	CMS1

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

>A>		BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001			Feb CMS1

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER

>D>		BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001			Feb CMS1

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER

>D>			@ BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML; 120MG/100ML;220MG/100ML	N018840	001	Jun 29, 1983	Feb	CMS1

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

>A>			@ BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML; 120MG/100ML;220MG/100ML	N018840	001	Jun 29, 1983	Feb	CMS1

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

			@ EUROHLTH INTL SARL	5MG/ML	A070313	001	Dec 16, 1985	Jan	CAHN

TABLET;ORAL

DIAZEPAM

			DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan	NEWA
				5MG	A070228	003	Sep 26, 1985	Jan	NEWA

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

>A>	AB		BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb	NEWA

ZIPSOR

>D>		+	DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb	CFTG
>A>	AB	+		25MG	N022202	001	Jun 16, 2009	Feb	CFTG

DICLOFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

	AT		RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

>D>	AB		ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb	CRLD
>A>	AB	+		100MG	A075910	001	Jan 07, 2002	Feb	CRLD

VOLTAREN-XR

>D>	AB	+	NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb	DISC
>A>			@	100MG	N020254	001	Mar 08, 1996	Feb	DISC

DICYCLOMINE HYDROCHLORIDE

SYRUP;ORAL

BENTYL

			@ APTALIS PHARMA US	10MG/5ML	N007961	002	Oct 15, 1984	Jan	DISC

DICYCLOMINE HYDROCHLORIDE

		+	MIKART	10MG/5ML	A040169	001	Mar 24, 2005	Jan	CRLD

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

			@ ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan	DISC
			@	180MG	A074852	002	Oct 10, 1997	Jan	DISC
			@	240MG	A074852	003	Oct 10, 1997	Jan	DISC
	AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan	CAHN
	AB3			180MG	A075116	002	Dec 23, 1999	Jan	CAHN
	AB3			240MG	A075116	003	Dec 23, 1999	Jan	CAHN
	AB3			300MG	A075116	004	Dec 23, 1999	Jan	CAHN

DINOPROSTONE

INSERT, EXTENDED RELEASE;VAGINAL

CERVIDIL

		+	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995	Jan	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

>A>			@ HIKMA PHARMS	50MG	A083567	001		Feb	CAHN
>D>			@ HIKMA PHARMS LLC	50MG	A083567	001		Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

>A>		@ AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb	CAHN
>A>		@	EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb	CAHN
>D>		@ SANDOZ	EQ 100MG BASE	A070470	001	Dec 10, 1985	Feb	CAHN
>D>		@	EQ 150MG BASE	A070471	001	Dec 10, 1985	Feb	CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

	AB	ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013	Jan	CAHN

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

>D>	AB	IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb	DISC
>A>		@	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Feb	DISC
>D>	AB		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb	DISC
>A>		@	EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Feb	DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

		@ TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Jan	CAHN

DOCETAXEL

SOLUTION;IV (INFUSION)

DOCETAXEL

		EAGLE PHARMS	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jan	CAHN
			80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jan	CAHN
			160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan	CAHN

DOLASETRON MESYLATE

INJECTABLE;INJECTION

ANZEMET

	+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Jan	CAHN
	+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Jan	CAHN
	+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Jan	CAHN

TABLET;ORAL

ANZEMET

		US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Jan	CAHN
	+		100MG	N020623	002	Sep 11, 1997	Jan	CAHN

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb	NEWA
	AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jan	NEWA

DOXEPIN HYDROCHLORIDE

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

	AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan	NEWA
	AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan	NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

>A>	AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb	NEWA
>A>	AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb	NEWA
>A>	AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

MELAMISA

	AB	NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan	NEWA

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

	AB		BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan CAHN
>A>	AB		INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb NEWA

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

TENSILON

		@	TELIGENT PHARMA INC	10MG/ML	N007959	001		Jan CAHN

TENSILON PRESERVATIVE FREE

		@	TELIGENT PHARMA INC	10MG/ML	N007959	002		Jan CAHN

EFAVIRENZ

TABLET;ORAL

>A> EFAVIRENZ

>A>	AB		MYLAN LABS LTD	600MG	A091471	001	Feb 17, 2016	Feb NEWA

SUSTIVA

>D>		+	BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Feb CFTG
>A>	AB	+		600MG	N021360	002	Feb 01, 2002	Feb CFTG

ELBASVIR; GRAZOPREVIR

TABLET;ORAL

ZEPATIER

		+	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016	Jan NEWA

EPINEPHRINE HYDROCHLORIDE

>D> SOLUTION;IV (INFUSION), INTRAOCULAR

>D> EPINEPHRINE

>D>			BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb CDFR

>A> SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

>A> EPINEPHRINE

>A>			BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb CDFR

ERGOCALCIFEROL

CAPSULE;ORAL

DRISDOL

	AA	+	US PHARM HOLDINGS	50,000 IU	N003444	001		Jan CAHN

VITAMIN D

	AA		BIONPHARMA INC	50,000 IU	A080704	001		Jan CAHN

ERYTHROMYCIN

SOLUTION;TOPICAL

>D> C-SOLVE-2

>D>	AT		FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb DISC
>A>		@		2%	A062468	001	Jul 03, 1985	Feb DISC

>D> ERYTHRO-STATIN

>D>	AT		HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb DISC
>A>		@		2%	A064101	001	Oct 22, 1996	Feb DISC

ERYTHROMYCIN

	AT	+	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan CRLD
	AT		PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan CRLD

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

			ALLERGAN PHARMS INTL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan CAHN
		+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan CAHN

TABLET;ORAL

FEMTRACE

			ALLERGAN PHARMS INTL	0.45MG	N021633	001	Aug 20, 2004	Jan CAHN
				0.9MG	N021633	002	Aug 20, 2004	Jan CAHN
		+		1.8MG	N021633	003	Aug 20, 2004	Jan CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

	AB		JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan NEWA

ZOVIA 1/50E-28

	AB	+	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE;ORAL

FEMCON FE

AB	+	ALLERGAN PHARMS INTL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+	ALLERGAN PHARMS INTL	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

FEMHRT

AB		ALLERGAN PHARMS INTL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan CAHN
	@		0.005MG;1MG	N021065	002	Oct 15, 1999	Jan CAHN

LO LOESTRIN FE

	+	ALLERGAN PHARMS INTL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan CAHN

TABLET;ORAL-21

ESTROSTEP 21

	@	ALLERGAN PHARMS INTL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jan CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan NEWA

TABLET;ORAL-28

ESTROSTEP FE

AB	+	ALLERGAN PHARMS INTL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan CAHN

TABLET, CHEWABLE;ORAL

MINASTRIN 24 FE

	+	ALLERGAN PHARMS INTL	0.02MG;1MG	N203667	001	May 08, 2013	Jan CAHN

TABLET, CHEWABLE, TABLET;ORAL

LO MINASTRIN FE

	+	ALLERGAN PHARMS INTL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

>A> AB		GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A204057	001	Feb 23, 2016	Feb NEWA
AB		JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG	A201897	001	Jan 27, 2016	Jan NEWA
AB			0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan NEWA

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB		BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan CAHN

ETODOLAC

CAPSULE;ORAL

ETODOLAC

>D>	@	AAIPHARMA LLC	300MG	A074929	001	Jan 30, 1998	Feb CAHN
>A>	@	LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb CAHN

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

>A> AP		HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb NEWA

EXEMESTANE

TABLET;ORAL

EXEMESTANE

AB		ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan CAHN

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON PEN

>A>	+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb NEWA

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

>A>	@	AUROLIFE PHARMA LLC	EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb CAHN
>D>	@	SANDOZ	EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb CAHN

TABLET;ORAL
FENOPROFEN CALCIUM

>A>		@ AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb	CAHN
>D>		@ SANDOZ	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb	CAHN

FENTANYL
FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-12

	AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan	NEWA

FESOTERODINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

		@ ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan	DISC
		@	8MG	A204827	002	Dec 10, 2015	Jan	DISC

FLUCONAZOLE
FOR SUSPENSION;ORAL
FLUCONAZOLE

>D>	AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb	DISC
>A>		@	50MG/5ML	A076332	001	Jul 29, 2004	Feb	DISC
>D>	AB		200MG/5ML	A076332	002	Jul 29, 2004	Feb	DISC
>A>		@	200MG/5ML	A076332	002	Jul 29, 2004	Feb	DISC

INJECTABLE;INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan	DISC
		@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan	DISC

FLUDEOXYGLUCOSE F-18
INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

>D>	AP	IBA MOLECULAR N AM	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb	CAHN
>A>	AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb	CAHN

FLUOROURACIL
INJECTABLE;INJECTION
FLUOROURACIL

>A>	AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb	NEWA
>A>	AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb	NEWA
		@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan	CAHN

FLUOXETINE HYDROCHLORIDE
TABLET;ORAL
SARAFEM

	AB1	ALLERGAN PHARMS INTL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan	CAHN
	AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan	CAHN
	AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan	CAHN

FLURAZEPAM HYDROCHLORIDE
CAPSULE;ORAL
FLURAZEPAM HYDROCHLORIDE

>A>		@ AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991	Feb	CAHN
>A>		@	30MG	A071717	001	Jul 31, 1991	Feb	CAHN
>D>		@ SANDOZ	15MG	A071716	001	Jul 31, 1991	Feb	CAHN
>D>		@	30MG	A071717	001	Jul 31, 1991	Feb	CAHN

FLURBIPROFEN
TABLET;ORAL
FLURBIPROFEN

>A>		@ AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995	Feb	CAHN
>A>		@	100MG	A074448	002	Jul 28, 1995	Feb	CAHN
>D>		@ SANDOZ	50MG	A074448	001	Jul 28, 1995	Feb	CAHN
>D>		@	100MG	A074448	002	Jul 28, 1995	Feb	CAHN

FLUVASTATIN SODIUM
TABLET, EXTENDED RELEASE;ORAL
FLUVASTATIN SODIUM

	AB	TEVA PHARMS USA	80MG	A079011	001	Jan 27, 2016	Jan	NEWA

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

>A>		@ NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb	CAHN
>A>		@	50MG	A075900	002	Feb 23, 2006	Feb	CAHN
>A>		@	100MG	A075900	003	Feb 23, 2006	Feb	CAHN
>D>		@ SUN PHARM INDS INC	25MG	A075900	001	Feb 23, 2006	Feb	CAHN
>D>		@	50MG	A075900	002	Feb 23, 2006	Feb	CAHN
>D>		@	100MG	A075900	003	Feb 23, 2006	Feb	CAHN

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

		@ ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan	DISC
		@	20MG	A076620	002	Oct 15, 2004	Jan	DISC
		@	40MG	A076620	003	Oct 15, 2004	Jan	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

		@ ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan	DISC
		@	20MG;12.5MG	A076608	002	Dec 03, 2004	Jan	DISC
>D>	AB	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb	DISC
>A>		@	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb	DISC
>D>	AB		20MG;12.5MG	A076739	002	Dec 17, 2004	Feb	DISC
>A>		@	20MG;12.5MG	A076739	002	Dec 17, 2004	Feb	DISC

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

>A>	AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb	NEWA

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

		@ EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan	CAHN
>D>	AP	+ LUITPOLD	10MG/ML	N018579	001	Nov 30, 1983	Feb	DISC
>A>		@	10MG/ML	N018579	001	Nov 30, 1983	Feb	DISC

TABLET;ORAL

LASIX

	AB	US PHARM HOLDINGS	20MG	N016273	002		Jan	CAHN
	AB		40MG	N016273	001		Jan	CAHN
	AB	+	80MG	N016273	003		Jan	CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

>A>	AB	SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb	NEWA
>A>	AB		300MG	A204989	002	Feb 18, 2016	Feb	NEWA
>A>	AB		400MG	A204989	003	Feb 18, 2016	Feb	NEWA

SOLUTION;ORAL

GABAPENTIN

>A>	AA	TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb	NEWA

TABLET;ORAL

GABAPENTIN

	AB	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan	NEWA
	AB		800MG	A205101	002	Feb 04, 2016	Jan	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB	IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb	DISC
>A>		@	EQ 8MG BASE	A078484	001	May 27, 2009	Feb	DISC
>D>	AB		EQ 16MG BASE	A078484	002	May 27, 2009	Feb	DISC
>A>		@	EQ 16MG BASE	A078484	002	May 27, 2009	Feb	DISC
>D>	AB		EQ 24MG BASE	A078484	003	May 27, 2009	Feb	DISC
>A>		@	EQ 24MG BASE	A078484	003	May 27, 2009	Feb	DISC

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

		@	ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan DISC
		@		2MG	A076995	002	Apr 27, 2010	Jan DISC
		@		4MG	A076995	003	Apr 27, 2010	Jan DISC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

		@	COREPHARMA	1.25MG;250MG	A076731	001	Nov 19, 2004	Jan DISC
		@		2.5MG;500MG	A076731	002	Nov 19, 2004	Jan DISC
		@		5MG;500MG	A076731	003	Nov 19, 2004	Jan DISC
>A>	AB		ZYDUS PHARMS USA INC	1.25MG;250MG	A206748	001	Feb 29, 2016	Feb NEWA
>A>	AB			2.5MG;500MG	A206748	002	Feb 29, 2016	Feb NEWA
>A>	AB			5MG;500MG	A206748	003	Feb 29, 2016	Feb NEWA

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

>D>	AP		HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
>A>	AP	+		0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
>D>			ROBINUL					
>D>	AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Feb DISC
>A>		@		0.2MG/ML	N017558	001		Feb DISC

TABLET;ORAL

GLYCOPYRROLATE

	AA		RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan CAHN
	AA			2MG	A040821	002	Dec 29, 2008	Jan CAHN
			ROBINUL					
	AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jan CAHN
			ROBINUL FORTE					
	AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jan CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

	AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
	AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	AP		HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
	AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

	AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

		@	ROXANE	2MG	A071130	001	Feb 17, 1987	Jan CAHN
		@	VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
		@		1MG	A071235	003	Nov 03, 1986	Jan CMS1
		@		5MG	A071235	004	Nov 03, 1986	Jan CMS1
		@		10MG	A071235	005	Jul 20, 1987	Jan CMS1

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

		@	ACTAVIS ELIZABETH	1.5MG;5MG	A040295	001	Dec 01, 2000	Jan CMS1

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

>A>		@	WATSON LABS	25MG;15MG	A085827	001		Feb CMS1

HYDRALAZINE AND HYDROCHLORTHIAZIDE

>D>		@	WATSON LABS	25MG;15MG	A085827	001		Feb CMS1

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

>A>		@ AUROLIFE PHARMA LLC	25MG	A083899	001			Feb CAHN
>A>		@	50MG	A085219	001			Feb CAHN
>D>		@ SANDOZ	25MG	A083899	001			Feb CAHN
>D>		@	50MG	A085219	001			Feb CAHN

ORETIC

		@ ABBVIE	50MG	N011971	002			Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

	AB	INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016		Jan NEWA
	AB		12.5MG;300MG	A203036	002	Jan 15, 2016		Jan NEWA
			25MG;300MG	A203036	003	Jan 15, 2016		Jan NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

ZESTORETIC

	AB	ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993		Jan CAHN
	AB	+	12.5MG;20MG	N019888	001	Sep 20, 1990		Jan CAHN
	AB	+	25MG;20MG	N019888	002	Jul 20, 1989		Jan CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

	AB	PRINSTON INC	12.5MG;80MG	A206083	001	Feb 08, 2016		Jan NEWA
	AB		12.5MG;160MG	A206083	002	Feb 08, 2016		Jan NEWA
	AB		12.5MG;320MG	A206083	003	Feb 08, 2016		Jan NEWA
	AB		25MG;160MG	A206083	004	Feb 08, 2016		Jan NEWA
	AB		25MG;320MG	A206083	005	Feb 08, 2016		Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

		@ ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010		Jan DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

PEDIOTIC

		@ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987		Jan DISC

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

		@ SERB SA	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006		Jan CAHN
		+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011		Jan CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

>D>		@ WATSON LABS	200MG	A040133	001	Nov 30, 1995		Feb CMFD
>A>	AB		200MG	A040133	001	Nov 30, 1995		Feb CMFD

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION

HYDROXYPROGESTERONE CAPROATE

		+ ASPEN GLOBAL INC	250MG/ML	A200271	001	Aug 24, 2015		Jan CAHN

SOLUTION;INTRAMUSCULAR

MAKENA

>A>		+ LUMARA HEALTH INC	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016		Feb NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

>A>		@ AUROLIFE PHARMA LLC	10MG	A087869	001	Dec 20, 1982		Feb CAHN
>A>		@	25MG	A087870	001	Dec 20, 1982		Feb CAHN
>A>		@	50MG	A087871	001	Dec 20, 1982		Feb CAHN
>D>		@ SANDOZ	10MG	A087869	001	Dec 20, 1982		Feb CAHN

TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

>D>		@	25MG	A087870	001	Dec 20, 1982	Feb	CAHN
>D>		@	50MG	A087871	001	Dec 20, 1982	Feb	CAHN

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS
IBANDRONATE SODIUM

	AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan	NEWA

TABLET;ORAL
IBANDRONATE SODIUM

>A>	AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb	NEWA

IBUPROFEN

TABLET;ORAL
IBUPROFEN

>A>		@ AUROLIFE PHARMA LLC	300MG	A070734	001	Jun 12, 1986	Feb	CAHN
>A>		@	400MG	A070735	001	Jun 12, 1986	Feb	CAHN
>A>		@	600MG	A070736	001	Jun 12, 1986	Feb	CAHN
>D>		@ SANDOZ	300MG	A070734	001	Jun 12, 1986	Feb	CAHN
>D>		@	400MG	A070735	001	Jun 12, 1986	Feb	CAHN
>D>		@	600MG	A070736	001	Jun 12, 1986	Feb	CAHN

IMIPRAMINE PAMOATE

CAPSULE;ORAL
IMIPRAMINE PAMOATE

>D>	AB	ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb	CRLD
>A>	AB	+	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb	CRLD
>D>		TOFRANIL-PM						
>D>	AB	+ MALLINCKRODT INC	EQ 75MG HCL	N017090	001		Feb	DISC
>A>		@	EQ 75MG HCL	N017090	001		Feb	DISC
>D>	AB		EQ 100MG HCL	N017090	004		Feb	DISC
>A>		@	EQ 100MG HCL	N017090	004		Feb	DISC
>D>	AB		EQ 125MG HCL	N017090	003		Feb	DISC
>A>		@	EQ 125MG HCL	N017090	003		Feb	DISC
>D>	AB		EQ 150MG HCL	N017090	002		Feb	DISC
>A>		@	EQ 150MG HCL	N017090	002		Feb	DISC

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION
INDIUM IN 111 CHLORIDE

		+ MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan	CAHN

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION
OCTREOSCAN

		+ MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan	CAHN

INDOCYANINE GREEN

INJECTABLE;INJECTION
INDOCYANINE GREEN

	AP	DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan	CAHN

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN

>D>		+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb	DISC
>A>		@	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb	DISC

INSULIN HUMAN

SOLUTION;SUBCUTANEOUS
HUMULIN R

		+ LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan	CAIN

HUMULIN R KWIKPEN

		+ LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

AP		SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan	CAHN
AP			100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan	CAHN

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

AP		AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan	NEWA
AP	+	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan	CTEC

KETOCONAZOLE

TABLET;ORAL

KETOCONAZOLE

	@	SUN PHARM INDS	200MG	A075314	001	Jun 15, 1999	Jan	CAHN

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

>A>	@	AUROLIFE PHARMA LLC	50MG	A074024	001	Dec 29, 1995	Feb	CAHN
>A>	@		75MG	A074024	002	Dec 29, 1995	Feb	CAHN
>D>	@	SANDOZ	50MG	A074024	001	Dec 29, 1995	Feb	CAHN
>D>	@		75MG	A074024	002	Dec 29, 1995	Feb	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP		SAGENT STRIDES	5MG/ML	A079134	001	Feb 03, 2010	Jan	CTNA

TRANDATE

	@	SEBELA IRELAND LTD	5MG/ML	N019425	001	Dec 31, 1985	Jan	CAHN

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB		NOSTRUM LABS INC	100MG	A075215	001	Jul 29, 1999	Jan	CAHN
AB			200MG	A075215	002	Jul 29, 1999	Jan	CAHN
AB			300MG	A075215	003	Jul 29, 1999	Jan	CAHN

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

>A> AB		MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb	NEWA
>A> AB			300MG	A204528	002	Mar 04, 2016	Feb	NEWA

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB	+	GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009	Jan	CRLD

LETROZOLE

TABLET;ORAL

LETROZOLE

AB		KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jan	CAHN

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP		AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan	NEWA
>D>		TABLET;ORAL						
>D>		SPRITAM						
>D>		APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb	CDFR
>D>			500MG	N207958	002	Jul 31, 2015	Feb	CDFR
>D>			750MG	N207958	003	Jul 31, 2015	Feb	CDFR
>D>			1GM	N207958	004	Jul 31, 2015	Feb	CDFR

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

>A> AB		INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb	NEWA
>A> AB			750MG	A204511	002	Feb 23, 2016	Feb	NEWA
>A>		TABLET, FOR SUSPENSION;ORAL						
>A>		SPRITAM						
>A>		APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb	CDFR

>A>		TABLET, FOR SUSPENSION;ORAL						
>A>		SPRITAM						
>A>			500MG	N207958	002	Jul 31, 2015	Feb	CDFR
>A>			750MG	N207958	003	Jul 31, 2015	Feb	CDFR
>A>			1GM	N207958	004	Jul 31, 2015	Feb	CDFR
		LEVOFLOXACIN						
		INJECTABLE;INJECTION						
		LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan	NEWA
	AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan	NEWA
	AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan	NEWA
		SOLUTION/DROPS;OPHTHALMIC						
		LEVOFLOXACIN						
	AT +	RISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan	CAHN
		LIDOCAINE						
		OINTMENT;TOPICAL						
		LIDOCAINE						
	AT	TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan	NEWA
		LIDOCAINE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	HOSPIRA	400MG/100ML	N018388	002		Feb	DISC
>A>	@		400MG/100ML	N018388	002		Feb	DISC
		LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982	Feb	DISC
>A>	@		800MG/100ML	N018388	003	Nov 05, 1982	Feb	DISC
		JELLY;TOPICAL						
		ANESTACON						
	@	BIONPHARMA INC	2%	A080429	001		Jan	CAHN
		LINEZOLID						
		SOLUTION;IV (INFUSION)						
		LINEZOLID						
>A>	AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	Feb	NEWA
		TABLET;ORAL						
		LINEZOLID						
	AB	GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Jan	NEWA
		LISINOPRIL						
		TABLET;ORAL						
		ZESTRIL						
	AB	ALVOGEN MALTA	2.5MG	N019777	005	Apr 29, 1993	Jan	CAHN
	AB		5MG	N019777	001	May 19, 1988	Jan	CAHN
	AB		10MG	N019777	002	May 19, 1988	Jan	CAHN
	AB		20MG	N019777	003	May 19, 1988	Jan	CAHN
	AB		30MG	N019777	006	Jan 20, 1999	Jan	CAHN
	AB +		40MG	N019777	004	May 19, 1988	Jan	CAHN
		LITHIUM CARBONATE						
		CAPSULE;ORAL						
		LITHIUM CARBONATE						
>A>	AB	DELCOR ASSET CORP	150MG	A076243	002	Feb 24, 2003	Feb	CAHN
>A>	AB		300MG	A076243	001	Jun 27, 2002	Feb	CAHN
>A>	AB		600MG	A078763	001	Apr 15, 2008	Feb	CAHN
>D>	AB	HIKMA INTL PHARMS	150MG	A076243	002	Feb 24, 2003	Feb	CAHN
>D>	AB		300MG	A076243	001	Jun 27, 2002	Feb	CAHN
>D>	AB	HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Feb	CAHN
	AB		600MG	A078763	001	Apr 15, 2008	Jan	CMFD
		LOMITAPIDE MESYLATE						
		CAPSULE;ORAL						
		JUXTAPID						
		AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CRLD
	+		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CRLD

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

>D>			IMODIUM					
>D>	AB	+	J AND J CONSUMER INC	2MG	N017694	001		Feb DISC
>A>		@		2MG	N017694	001		Feb DISC
			LOPERAMIDE HYDROCHLORIDE					
>D>	AB		MYLAN	2MG	A072741	001	Sep 18, 1991	Feb CRLD
>A>	AB	+		2MG	A072741	001	Sep 18, 1991	Feb CRLD

LOXAPINE

POWDER;INHALATION

			ADASUVE					
>A>		+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb CAHN
>D>		+	TEVA PHARMS USA INC	10MG	N022549	001	Dec 21, 2012	Feb CAHN

MAGNESIUM SULFATE

INJECTABLE;INJECTION

			MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
>A>	AP		FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb NEWA
>D>		+	HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb CFTG
>A>	AP	+		1GM/100ML	N020488	001	Jul 11, 1995	Feb CFTG
>A>	AP		HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb NEWA
>A>			MAGNESIUM SULFATE IN PLASTIC CONTAINER					
>A>	AP		FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb NEWA
>A>	AP			4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb NEWA
>D>		+	HOSPIRA	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
>A>	AP	+		4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
>D>		+		4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG
>A>	AP	+		4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

			MAGNESIUM SULFATE					
		+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan NEWA
		+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

			MECLIZINE HYDROCHLORIDE					
		@	RISING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan CAHN
		@		25MG	A040179	002	Jan 30, 1997	Jan CAHN

MEGESTROL ACETATE

SUSPENSION;ORAL

			MEGACE ES					
>A>	AB	+	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005	Feb CAHN
>D>	AB	+	PAR PHARM	125MG/ML	N021778	001	Jul 05, 2005	Feb CAHN

MELOXICAM

TABLET;ORAL

			MELOXICAM					
		@	SUN PHARM INDS	7.5MG	A077935	001	Jul 19, 2006	Jan CAHN
		@		15MG	A077935	002	Jul 19, 2006	Jan CAHN

MELPHALAN

TABLET;ORAL

			ALKERAN					
		+	APOTEX INC	2MG	N014691	002		Jan CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

			ALKERAN					
	AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

			DEMEROL					
		@	US PHARM HOLDINGS	25MG/ML	N005010	007		Jan CAHN
		@		50MG/ML	N005010	002		Jan CAHN
		@		75MG/ML	N005010	009		Jan CAHN
		@		100MG/ML	N005010	003		Jan CAHN

		SYRUP;ORAL						
		DEMEROL						
		@ US PHARM HOLDINGS	50MG/5ML	N005010	005			Jan CAHN
		TABLET;ORAL						
		DEMEROL						
	AA	+ US PHARM HOLDINGS	50MG	N005010	001			Jan CAHN
	AA	+	100MG	N005010	004			Jan CAHN
		MEPROBAMATE						
		TABLET;ORAL						
		MEPROBAMATE						
>A>		@ AUROLIFE PHARMA LLC	400MG	A080655	001			Feb CAHN
>D>		@ SANDOZ	400MG	A080655	001			Feb CAHN
		MERCAPTOPURINE						
		TABLET;ORAL						
		PURINETHOL						
		@ STASON PHARMS	50MG	N009053	002			Jan CAHN
		MESALAMINE						
		CAPSULE, DELAYED RELEASE;ORAL						
		DELZICOL						
		+ ALLERGAN PHARMS INTL	400MG	N204412	001	Feb 01, 2013		Jan CAHN
		TABLET, DELAYED RELEASE;ORAL						
		ASACOL						
		@ ALLERGAN PHARMS INTL	400MG	N019651	001	Jan 31, 1992		Jan CAHN
		ASACOL HD						
		+ ALLERGAN PHARMS INTL	800MG	N021830	001	May 29, 2008		Jan CAHN
		METFORMIN HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		GLUMETZA						
	AB3	SANTARUS INC	500MG	N021748	001	Jun 03, 2005		Jan CTEC
	AB3	+	1GM	N021748	002	Jun 03, 2005		Jan CTEC
		METHENAMINE HIPPURATE						
		TABLET;ORAL						
		HIPREX						
	AB	+ US PHARM HOLDINGS	1GM	N017681	001			Jan CAHN
		METHIMAZOLE						
		TABLET;ORAL						
		METHIMAZOLE						
	AB	RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012		Jan CAHN
	AB		10MG	A202068	002	Mar 07, 2012		Jan CAHN
		METHOCARBAMOL						
		TABLET;ORAL						
		METHOCARBAMOL						
>D>	AA	SANDOZ	500MG	A084616	001			Feb DISC
>A>		@	500MG	A084616	001			Feb DISC
>D>	AA		750MG	A084615	001			Feb DISC
>A>		@	750MG	A084615	001			Feb DISC
		METHOTREXATE SODIUM						
		INJECTABLE;INJECTION						
		METHOTREXATE SODIUM PRESERVATIVE FREE						
	AP	SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009		Jan CAHN
	AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009		Jan CAHN
	AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009		Jan CAHN
		METHYLERGONOVINE MALEATE						
		TABLET;ORAL						
		METHERGINE						
		@ EDISON THERAPS LLC	0.2MG	N006035	003			Jan DISC
		METHYLERGONOVINE MALEATE						
		+ NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011		Jan CRLD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AA		NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
>A>	AA			10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN
>D>	AA		SUN PHARM INDS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
>D>	AA			10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB		TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb NEWA
>A>	AB			20MG	A204772	002	Feb 29, 2016	Feb NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

>A>	AP		HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb NEWA
>A>	AP			EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb NEWA
	AP		SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan CAHN
	AP			EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan CAHN
	AP			EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan CAHN
	AP			EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan CAHN
	AP			EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan CAHN

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

	AB		NOSTRUM LABS INC	250MG	A070772	001	Jul 16, 1986	Jan CAHN
	AB			500MG	A070773	001	Jul 16, 1986	Jan CAHN

MICONAZOLE

TABLET;BUCCAL

ORAVIG

		+	MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Jan CAHN

MIGLITOL

TABLET;ORAL

GLYSET

>D>	AB		PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb CRLD
>A>	AB	+		25MG	N020682	001	Dec 18, 1996	Feb CRLD
>D>	AB	+		100MG	N020682	003	Dec 18, 1996	Feb CRLD
>A>	AB			100MG	N020682	003	Dec 18, 1996	Feb CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

		@	LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan DISC
				12.5MG	A205071	001	Jan 27, 2016	Jan NEWA
		@		25MG	A205071	002	Jan 27, 2016	Jan DISC
				25MG	A205071	002	Jan 27, 2016	Jan NEWA
		@		50MG	A205071	003	Jan 27, 2016	Jan DISC
				50MG	A205071	003	Jan 27, 2016	Jan NEWA
		@		100MG	A205071	004	Jan 27, 2016	Jan DISC
				100MG	A205071	004	Jan 27, 2016	Jan NEWA

MINOCYCLINE HYDROCHLORIDE

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

	AB		SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan NEWA
	AB			EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan NEWA
	AB			EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan NEWA

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

		@	ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003	Jan DISC
		@		30MG	A076336	002	Jun 20, 2003	Jan DISC
		@		45MG	A076336	003	Jun 20, 2003	Jan DISC

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP		EUROHLTH INTL SARL	5MG/VIAL	A064180	001	Dec 23, 1999		Jan CAHN
AP			20MG/VIAL	A064180	002	Dec 23, 1999		Jan CAHN

MODAFINIL

TABLET;ORAL

MODAFINIL

AB		WATSON LABS INC	100MG	A076715	001	Nov 01, 2012		Jan CAHN
AB			200MG	A076715	002	Nov 01, 2012		Jan CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

>D> AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007		Feb CTEC
>A> AB	+		10MG	N020616	008	Apr 20, 2007		Feb CTEC
>D> AB1			20MG	N020616	001	Jul 03, 1996		Feb CTEC
>A> AB			20MG	N020616	001	Jul 03, 1996		Feb CTEC
>D> AB1			30MG	N020616	004	Mar 09, 2001		Feb CTEC
>A> AB			30MG	N020616	004	Mar 09, 2001		Feb CTEC
>D> AB1			40MG	N020616	009	Jul 09, 2012		Feb CTEC
>A> AB			40MG	N020616	009	Jul 09, 2012		Feb CTEC
>D> AB1			50MG	N020616	002	Jul 03, 1996		Feb CTEC
>A> AB			50MG	N020616	002	Jul 03, 1996		Feb CTEC
>D> AB1			60MG	N020616	005	Mar 09, 2001		Feb CTEC
>A> AB			60MG	N020616	005	Mar 09, 2001		Feb CTEC
>D> AB1			70MG	N020616	010	Jul 09, 2012		Feb CTEC
>A> AB			70MG	N020616	010	Jul 09, 2012		Feb CTEC
>D> AB1			80MG	N020616	006	Oct 27, 2006		Feb CTEC
>A> AB			80MG	N020616	006	Oct 27, 2006		Feb CTEC
>D> AB1	+		100MG	N020616	003	Jul 03, 1996		Feb CTEC
>A> AB	+		100MG	N020616	003	Jul 03, 1996		Feb CTEC
>D> AB1	+		200MG	N020616	007	Feb 27, 2007		Feb CTEC
>A>	+		200MG	N020616	007	Feb 27, 2007		Feb CTEC

MORPHINE SULFATE

>D> AB1		PAR PHARM INC	20MG	A200812	001	Nov 10, 2011		Feb CTEC
>A> AB			20MG	A200812	001	Nov 10, 2011		Feb CTEC
>D> AB1			30MG	A200812	002	Nov 10, 2011		Feb CTEC
>A> AB			30MG	A200812	002	Nov 10, 2011		Feb CTEC
>D> AB1			50MG	A200812	003	Nov 10, 2011		Feb CTEC
>A> AB			50MG	A200812	003	Nov 10, 2011		Feb CTEC
>D> AB1			60MG	A200812	004	Nov 10, 2011		Feb CTEC
>A> AB			60MG	A200812	004	Nov 10, 2011		Feb CTEC
>D> AB1			80MG	A200812	005	Nov 10, 2011		Feb CTEC
>A> AB			80MG	A200812	005	Nov 10, 2011		Feb CTEC
>D> AB1			100MG	A200812	006	Nov 10, 2011		Feb CTEC
>A> AB			100MG	A200812	006	Nov 10, 2011		Feb CTEC
>D> AB1		TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014		Feb CTEC
>A> AB			20MG	A202718	001	Dec 29, 2014		Feb CTEC
>D> AB1			30MG	A202718	002	Dec 29, 2014		Feb CTEC
>A> AB			30MG	A202718	002	Dec 29, 2014		Feb CTEC
>D> AB1			40MG	A202718	007	Jun 03, 2015		Feb CTEC
>A> AB			40MG	A202718	007	Jun 03, 2015		Feb CTEC
>D> AB1			50MG	A202718	003	Dec 29, 2014		Feb CTEC
>A> AB			50MG	A202718	003	Dec 29, 2014		Feb CTEC
>D> AB1			60MG	A202718	004	Dec 29, 2014		Feb CTEC
>A> AB			60MG	A202718	004	Dec 29, 2014		Feb CTEC
>D> AB1			70MG	A202718	008	Jun 03, 2015		Feb CTEC
>A> AB			70MG	A202718	008	Jun 03, 2015		Feb CTEC
>D> AB1			80MG	A202718	005	Dec 29, 2014		Feb CTEC
>A> AB			80MG	A202718	005	Dec 29, 2014		Feb CTEC
>D> AB1			100MG	A202718	006	Dec 29, 2014		Feb CTEC
>A> AB			100MG	A202718	006	Dec 29, 2014		Feb CTEC
>D> AB1		UPSHER SMITH	10MG	A202104	001	Jun 03, 2013		Feb CTEC
>A> AB			10MG	A202104	001	Jun 03, 2013		Feb CTEC
>D> AB1			20MG	A202104	002	Jun 03, 2013		Feb CTEC
>A> AB			20MG	A202104	002	Jun 03, 2013		Feb CTEC
>D> AB1			30MG	A202104	003	Jun 03, 2013		Feb CTEC
>A> AB			30MG	A202104	003	Jun 03, 2013		Feb CTEC
>D> AB1			50MG	A202104	004	Jun 03, 2013		Feb CTEC
>A> AB			50MG	A202104	004	Jun 03, 2013		Feb CTEC

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

>D>	AB1			60MG	A202104	005	Jun 03, 2013	Feb CTEC
>A>	AB			60MG	A202104	005	Jun 03, 2013	Feb CTEC
>D>	AB1			80MG	A202104	006	Jun 03, 2013	Feb CTEC
>A>	AB			80MG	A202104	006	Jun 03, 2013	Feb CTEC
>D>	AB1			100MG	A202104	007	Jun 03, 2013	Feb CTEC
>A>	AB			100MG	A202104	007	Jun 03, 2013	Feb CTEC

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL
MOXIFLOXACIN HYDROCHLORIDE

	AB		CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan NEWA

NAPROXEN

TABLET;ORAL
NAPROSYN

>A>	AB		ATNAHS PHARMA US	250MG	N017581	002		Feb CAHN
>A>	AB			375MG	N017581	003		Feb CAHN
>A>	AB	+		500MG	N017581	004	Apr 15, 1982	Feb CAHN
>D>	AB		ROCHE PALO	250MG	N017581	002		Feb CAHN
>D>	AB			375MG	N017581	003		Feb CAHN
>D>	AB	+		500MG	N017581	004	Apr 15, 1982	Feb CAHN

NAPROXEN

>D>	AB		SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb DISC
>A>		@		250MG	A074140	001	Dec 21, 1993	Feb DISC
>D>	AB			375MG	A074140	002	Dec 21, 1993	Feb DISC
>A>		@		375MG	A074140	002	Dec 21, 1993	Feb DISC
>D>	AB			500MG	A074140	003	Dec 21, 1993	Feb DISC
>A>		@		500MG	A074140	003	Dec 21, 1993	Feb DISC

TABLET, DELAYED RELEASE;ORAL
EC-NAPROSYN

>A>	AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb CAHN
>A>	AB	+		500MG	N020067	003	Oct 14, 1994	Feb CAHN
>D>	AB	+	ROCHE PALO	375MG	N020067	002	Oct 14, 1994	Feb CAHN
>D>	AB	+		500MG	N020067	003	Oct 14, 1994	Feb CAHN

NAPROXEN

>D>	AB		SANDOZ	375MG	A075061	001	Feb 18, 1998	Feb DISC
>A>		@		375MG	A075061	001	Feb 18, 1998	Feb DISC
>D>	AB			500MG	A075061	002	Feb 18, 1998	Feb DISC
>A>		@		500MG	A075061	002	Feb 18, 1998	Feb DISC

NAPROXEN SODIUM

TABLET;ORAL
ANAPROX

>A>	AB		ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb CAHN
>D>	AB		HOFFMANN LA ROCHE	EQ 250MG BASE	N018164	001		Feb CAHN

ANAPROX DS

>A>	AB	+	ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb CAHN
>D>	AB	+	HOFFMANN LA ROCHE	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb CAHN

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL
NEFAZODONE HYDROCHLORIDE

>D>	AB		SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Feb DISC
>A>		@		50MG	A076409	001	Sep 16, 2003	Feb DISC
>D>	AB			100MG	A076409	002	Sep 16, 2003	Feb DISC
>A>		@		100MG	A076409	002	Sep 16, 2003	Feb DISC
>D>	AB			150MG	A076409	003	Sep 16, 2003	Feb DISC
>A>		@		150MG	A076409	003	Sep 16, 2003	Feb DISC
>D>	AB			200MG	A076409	004	Sep 16, 2003	Feb DISC
>A>		@		200MG	A076409	004	Sep 16, 2003	Feb DISC
>D>	AB			250MG	A076409	005	Sep 16, 2003	Feb DISC
>A>		@		250MG	A076409	005	Sep 16, 2003	Feb DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL
ADALAT CC

>A>	AB1		ALVOGEN	30MG	N020198	001	Apr 21, 1993	Feb CAHN
>A>	AB1	+		60MG	N020198	002	Apr 21, 1993	Feb CAHN
>A>	AB1	+		90MG	N020198	003	Apr 21, 1993	Feb CAHN
>D>	AB1		BAYER HLTHCARE	30MG	N020198	001	Apr 21, 1993	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
ADALAT CC

>D>	AB1	+		60MG	N020198	002	Apr 21, 1993	Feb CAHN
>D>	AB1	+		90MG	N020198	003	Apr 21, 1993	Feb CAHN
			NIFEDIPINE					
	AB1		VALEANT PHARMS NORTH	30MG	A075269	001	Dec 04, 2000	Jan CAHN
	AB1			60MG	A075269	002	Dec 04, 2000	Jan CAHN
	AB1			90MG	A076070	001	Aug 16, 2002	Jan CAHN

NIMODIPINE
CAPSULE;ORAL
NIMODIPINE

	AB	+	BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008	Jan CAHN

NITRIC OXIDE
GAS;INHALATION
INOMAX

		+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan CAHN

NITROFURANTOIN
SUSPENSION;ORAL
NITROFURANTOIN

>A>	AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb CAHN
>D>	AB		SUN PHARM INDS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb CAHN

NITROFURANTOIN, MACROCRYSTALLINE
CAPSULE;ORAL
NITROFURANTOIN

>A>	AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb NEWA
>A>	AB			50MG	A201722	002	Feb 16, 2016	Feb NEWA
>A>	AB			100MG	A201722	003	Feb 16, 2016	Feb NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE
CAPSULE;ORAL
MACROBID

	AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan CAHN

NIZATIDINE
SOLUTION;ORAL

>D>			AXID					
>D>	AA	+	BRAINTREE	15MG/ML	N021494	001	May 25, 2004	Feb DISC
>A>		@		15MG/ML	N021494	001	May 25, 2004	Feb DISC
			NIZATIDINE					
>D>	AA		AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Feb CRLD
>A>		+		15MG/ML	A090576	001	Nov 18, 2009	Feb CRLD

NOREPINEPHRINE BITARTRATE
INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

	AP		CLARIS	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Jan CAHN

NORETHINDRONE
TABLET;ORAL-28
NOR-QD

	AB1	+	ALLERGAN PHARMS INTL	0.35MG	N017060	001		Jan CAHN

NORTRIPTYLINE HYDROCHLORIDE
CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

>A>		@	AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb CAHN
>A>		@		EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb CAHN
>A>		@		EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb CAHN
>A>		@		EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb CAHN
>D>		@	SANDOZ	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb CAHN
>D>		@		EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb CAHN
>D>		@		EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb CAHN
>D>		@		EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb CAHN

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

			@ WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Jan DISC
			@	EQ 1MG BASE/ML	A090986	002	May 11, 2011	Jan DISC

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

>D>			@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb CMS1
			@	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Jan DISC
>D>			@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb CMS1
			@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Jan DISC
>D>			@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb CMS1
			@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Jan DISC

OCTREOTIDE ACETATE PRESERVATIVE FREE

>A>			@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb CMS1
>A>			@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb CMS1
>A>			@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb CMS1

OFLOXACIN

SOLUTION/DROPS;OTIC

FLOXIN OTIC

>D>								
>D>	AT	+	DAIICHI	0.3%	N020799	001	Dec 16, 1997	Feb DISC
>A>			@	0.3%	N020799	001	Dec 16, 1997	Feb DISC

OFLOXACIN

>D>	AT		BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008	Feb CRLD
>A>	AT	+		0.3%	A076128	001	Mar 17, 2008	Feb CRLD

OLANZAPINE

TABLET;ORAL

OLANZAPINE

>A>	AB		INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb NEWA
>A>	AB			5MG	A203333	002	Mar 15, 2016	Feb NEWA
>A>	AB			7.5MG	A203333	003	Mar 15, 2016	Feb NEWA
>A>	AB			10MG	A203333	004	Mar 15, 2016	Feb NEWA
>A>	AB			15MG	A203333	005	Mar 15, 2016	Feb NEWA
>A>	AB			20MG	A203333	006	Mar 15, 2016	Feb NEWA
	AB		QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan NEWA
	AB			5MG	A204319	002	Jan 27, 2016	Jan NEWA
	AB			7.5MG	A204319	003	Jan 27, 2016	Jan NEWA
	AB			10MG	A204319	004	Jan 27, 2016	Jan NEWA
	AB			15MG	A204319	005	Jan 27, 2016	Jan NEWA
	AB			20MG	A204319	006	Jan 27, 2016	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

>A>	AB		INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb NEWA
>A>	AB			10MG	A203456	002	Mar 16, 2016	Feb NEWA
>A>	AB			15MG	A203456	003	Mar 16, 2016	Feb NEWA
>A>	AB			20MG	A203456	004	Mar 16, 2016	Feb NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

	AB		AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan CMS1

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

>A>	AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA

OXALIPLATIN

INJECTABLE;IV (INFUSION)

OXALIPLATIN

	AP		SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Jan CAHN
	AP			100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Jan CAHN

OXICONAZOLE NITRATE

CREAM;TOPICAL

>A>			OXICONAZOLE NITRATE					
>A>	AB		TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb NEWA
			OXISTAT					
>D>		+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb CFTG
>A>	AB	+		EQ 1% BASE	N019828	001	Dec 30, 1988	Feb CFTG

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

		OXYBUTYNIN CHLORIDE					
>A>	AB	ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb NEWA
>A>	AB		10MG	A207138	002	Feb 29, 2016	Feb NEWA
>A>	AB		15MG	A207138	003	Feb 29, 2016	Feb NEWA

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

		OXYCODONE HYDROCHLORIDE					
	AB	ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan CAHN
	AB		15MG	A202116	002	Dec 30, 2011	Jan CAHN
	AB		30MG	A202116	003	Dec 30, 2011	Jan CAHN

PACLITAXEL

INJECTABLE;INJECTION

		PACLITAXEL					
	AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan CAHN

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

		PAMIDRONATE DISODIUM					
	AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan CAHN
	AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

		PANTOPRAZOLE SODIUM					
	AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan NEWA
	AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan NEWA

PARICALCITOL

CAPSULE;ORAL

		PARICALCITOL					
	AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
	AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
	AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN
>A>	AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb NEWA
>A>	AB		2MCG	A206710	002	Feb 24, 2016	Feb NEWA
>A>	AB		4MCG	A206710	003	Feb 24, 2016	Feb NEWA

SOLUTION;INTRAVENOUS

		PARICALCITOL					
>A>	AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb NEWA
>A>	AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb NEWA
>A>	AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb NEWA

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

		PENTETATE CALCIUM TRISODIUM					
>A>		@ HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb CAHN
>D>		@ HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb CAHN

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

		PENTETATE ZINC TRISODIUM					
>A>		@ HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb CAHN
>D>		@ HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

TRENTAL

@	US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984		Jan CAHN

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB	WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015		Jan CAHN
AB		4MG	A205973	002	Dec 17, 2015		Jan CAHN
AB		8MG	A205973	003	Dec 17, 2015		Jan CAHN
AB		16MG	A205973	004	Dec 17, 2015		Jan CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

@	ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105	001	Jun 26, 2001		Jan CMS1

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

AA	INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012		Jan CAHN

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

@	TELIGENT PHARMA INC	1MG/0.5ML	N012223	002			Jan CAHN
@		10MG/ML	N012223	001			Jan CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	MYLAN PHARMS INC	20MG	A074118	001	Jun 15, 1993		Jan CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016		Jan NEWA
>A> AB	TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016		Feb NEWA
>A> AB		10MEQ	A201944	002	Mar 04, 2016		Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1	NOVEL LABS INC	10MEQ	A206347	001	Jan 21, 2016		Jan NEWA
AB1		20MEQ	A206347	002	Jan 21, 2016		Jan NEWA

PREDNISOLONE

TABLET;ORAL

PREDNISOLONE

>A>	@ AUROLIFE PHARMA LLC	5MG	A084773	001			Feb CAHN
>D>	@ SANDOZ	5MG	A084773	001			Feb CAHN

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB	BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013		Jan CAHN
AB		200MG	A200900	002	Aug 16, 2013		Jan CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

>A> AA	NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009		Feb CAHN
>D> AA	SUN PHARM INDS INC	6.25MG/5ML	A040891	001	Mar 13, 2009		Feb CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

@	SUN PHARM INDS	50MG	A084557	001			Jan CAHN

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

PYRIDOSTIGMINE BROMIDE

	AB		ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

>A>	AB		UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb NEWA
>A>	AB			EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb NEWA
>A>	AB			EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb NEWA
>A>	AB			EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb NEWA
>A>	AB			EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb NEWA
>A>	AB			EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

		@	ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan DISC
		@		EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan DISC
		@		EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan DISC
		@		EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

	AP	+	IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN

ZANTAC IN PLASTIC CONTAINER

		@	IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan CAHN
		@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan CAHN

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

>A>	AB		ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb NEWA
>A>	AB			EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb NEWA

RESERPINE

TABLET;ORAL

RESERPINE

>A>		@	HIKMA INTL PHARMS	0.1MG	A080975	001		Feb CAHN
>A>		@		0.25MG	A080975	002		Feb CAHN
>A>		@		1MG	A080975	003		Feb CAHN
>D>		@	HIKMA PHARMS LLC	0.1MG	A080975	001		Feb CAHN
>D>		@		0.25MG	A080975	002		Feb CAHN
>D>		@		1MG	A080975	003		Feb CAHN

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

		+	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan CAHN

RIFAMPIN

INJECTABLE;INJECTION

RIFAMPIN

>A>	AP		HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb NEWA
	AP		WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan NEWA

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

	AB		ALLERGAN PHARMS INTL	5MG	N020835	002	Apr 14, 2000	Jan CAHN
	AB			30MG	N020835	001	Mar 27, 1998	Jan CAHN
	AB	+		35MG	N020835	003	May 25, 2002	Jan CAHN
		@		75MG	N020835	004	Apr 16, 2007	Jan CAHN
	AB	+		150MG	N020835	005	Apr 22, 2008	Jan CAHN

TABLET, DELAYED RELEASE;ORAL

ATELVIA

	AB	+	ALLERGAN PHARMS INTL	35MG	N022560	001	Oct 08, 2010	Jan CAHN

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

	AB		ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan CAHN
	AB			9.5MG/24HR	A204403	002	Sep 03, 2015	Jan CAHN
	AB			13.3MG/24HR	A204403	003	Aug 31, 2015	Jan CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

EXELON

	AB	+	NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan CRLD

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

>A>	AB		ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb NEWA
>A>	AB			EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb NEWA
	AB		NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan CAHN
	AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan CAHN

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

>A>		@	TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb DISC
>A>				EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb NEWA
>A>		@		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb DISC
>A>				EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb NEWA
>A>		@		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb DISC
>A>				EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb NEWA

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

>D>	AB		SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb DISC
>A>		@		5MG	A076285	001	Dec 20, 2006	Feb DISC
>D>	AB			10MG	A076285	002	Dec 20, 2006	Feb DISC
>A>		@		10MG	A076285	002	Dec 20, 2006	Feb DISC
>D>	AB			20MG	A076285	003	Dec 20, 2006	Feb DISC
>A>		@		20MG	A076285	003	Dec 20, 2006	Feb DISC
>D>	AB			40MG	A076285	004	Dec 20, 2006	Feb DISC
>A>		@		40MG	A076285	004	Dec 20, 2006	Feb DISC
>D>	AB			80MG	A076285	005	Jun 23, 2006	Feb DISC
>A>		@		80MG	A076285	005	Jun 23, 2006	Feb DISC

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)

AMMONUL

>D>		+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb CFTG
>A>	AP	+		10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb CFTG

SODIUM PHENYLACETATE AND SODIUM BENZOATE

>A>	AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb NEWA

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

>A>			HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb NEWA

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

>D>	AP		IBA MOLECULAR N AM	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN
>A>	AP		ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>A>	AA		BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb NEWA
>A>	AA		INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb NEWA

SUCRALFATE

TABLET;ORAL

SUCRALFATE

AB		MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan CAHN

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

BRIDION

		ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan CPOT
	+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan CPOT

SULFAMETHOXAZOLE

TABLET;ORAL

SULFAMETHOXAZOLE

>A>		@ AUROLIFE PHARMA LLC	500MG	A085844	001		Feb CAHN
>D>		@ SANDOZ	500MG	A085844	001		Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

		@ ANI PHARMS INC	200MG/5ML;40MG/5ML	A077612	001	Nov 13, 2006	Jan CAHN

SULFISOXAZOLE

TABLET;ORAL

SULFISOXAZOLE

>A>		@ AUROLIFE PHARMA LLC	500MG	A085628	001		Feb CAHN
>D>		@ SANDOZ	500MG	A085628	001		Feb CAHN

SUMATRIPTAN

SPRAY;NASAL

IMITREX

>D>	+	GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997	Feb CFTG
>A> AB	+		5MG/SPRAY	N020626	001	Aug 26, 1997	Feb CFTG
>D>	+		20MG/SPRAY	N020626	003	Aug 26, 1997	Feb CFTG
>A> AB	+		20MG/SPRAY	N020626	003	Aug 26, 1997	Feb CFTG

>A> SUMATRIPTAN

>A> AB		LANNETT	5MG/SPRAY	A204841	001	Feb 19, 2016	Feb NEWA
>A> AB			20MG/SPRAY	A204841	002	Feb 19, 2016	Feb NEWA

SUMATRIPTAN SUCCINATE

POWDER;INHALATION

ONZETRA XSAIL

	+	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jan NEWA

SOLUTION;SUBCUTANEOUS

ZEMBRACE SYMTOUCH

		DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jan NEWA

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

		MIDATECH PHARMA US	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005	Jan CAHN

TABLET;ORAL

TAMOXIFEN CITRATE

		@ ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003	Jan DISC
		@	EQ 20MG BASE	A076179	002	Feb 20, 2003	Jan DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

ULTRA-TECHNEKOW FM

	+	MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
	@		0.25-3 CI/GENERATOR	N017243	002		Jan CAHN

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

		@ US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jan CAHN
		@	EQ 6MG BASE	N021200	002	Jul 24, 2002	Jan CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB		KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan NEWA
AB			20MG	A203898	002	Feb 10, 2016	Jan NEWA
AB			100MG	A203898	003	Feb 10, 2016	Jan NEWA
AB			140MG	A203898	004	Feb 10, 2016	Jan NEWA
AB			180MG	A203898	005	Feb 10, 2016	Jan NEWA
AB			250MG	A203898	006	Feb 10, 2016	Jan NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB		HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan NEWA
AB			25MG	A204574	002	Feb 03, 2016	Jan NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAINE HYDROCHLORIDE

>A>	+	ALCON RES LTD	0.5%	N208135	001	Feb 29, 2016	Feb NEWA

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

	+	NOSTRUM LABS INC	80MG/15ML	A085186	001		Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

AB		NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan CAHN
AB			200MG	A088321	001	Feb 21, 1985	Jan CAHN
	@		300MG	A087400	002	Jan 11, 1983	Jan CAHN

THEOPHYLLINE

AB		MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan CAHN
AB	+		600MG	A040560	002	Apr 21, 2006	Jan CAHN

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

XELJANZ XR

>A>	+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb NEWA

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

AB		ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Jan CAHN
AB			50MG	A078637	002	Feb 27, 2013	Jan CAHN
AB			100MG	A078637	003	Feb 27, 2013	Jan CAHN
AB			200MG	A078637	004	Feb 27, 2013	Jan CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP		AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan NEWA
>A> AP		NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

>A>	@	AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb CAHN
>D>	@	SANDOZ	50MG	A072484	001	Apr 30, 1990	Feb CAHN

TRETINOIN

CREAM;TOPICAL

TRETINOIN

>A> AB		ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Feb CAHN
>A> AB1			0.05%	A075265	001	Dec 24, 1998	Feb CAHN
>A> AB			0.1%	A075213	001	Dec 24, 1998	Feb CAHN
>D> AB		MATAWAN PHARMS	0.025%	A075264	001	Dec 24, 1998	Feb CAHN
>D> AB1			0.05%	A075265	001	Dec 24, 1998	Feb CAHN
>D> AB			0.1%	A075213	001	Dec 24, 1998	Feb CAHN

GEL;TOPICAL
TRETINOIN

>A>	AB	ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Feb	CAHN
>A>	AB		0.025%	A075529	001	Feb 22, 2000	Feb	CAHN
>D>	AB	MATAWAN PHARMS	0.01%	A075589	001	Jun 11, 2002	Feb	CAHN
>D>	AB		0.025%	A075529	001	Feb 22, 2000	Feb	CAHN

TRIMETHOPRIM HYDROCHLORIDE
SOLUTION;ORAL
PRIMSOL

	@	AYTU PHARMS	EQ 25MG BASE/5ML	A074374	001	Jun 23, 1995	Jan	CAHN
	+		EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jan	CAHN

VALPROIC ACID
CAPSULE;ORAL
VALPROIC ACID

AB		BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan	CAHN

CAPSULE, DELAYED RELEASE;ORAL
STAVZOR

	@	BIONPHARMA INC	125MG	N022152	001	Jul 29, 2008	Jan	CAHN
	@		250MG	N022152	002	Jul 29, 2008	Jan	CAHN
	@		500MG	N022152	003	Jul 29, 2008	Jan	CAHN

VANCOMYCIN HYDROCHLORIDE
INJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

AP		GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan	NEWA

VECURONIUM BROMIDE
INJECTABLE;INJECTION
VECURONIUM BROMIDE

AP		SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan	CAHN
AP			20MG/VIAL	A078274	002	Dec 29, 2008	Jan	CAHN

VERAPAMIL HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
CALAN SR

>D>	AB	+ PFIZER	180MG	N019152	002	Dec 15, 1989	Feb	DISC
>A>		@	180MG	N019152	002	Dec 15, 1989	Feb	DISC

VORICONAZOLE
TABLET;ORAL
VORICONAZOLE

AB		AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan	NEWA
AB			200MG	A206837	002	Jan 22, 2016	Jan	NEWA

XENON XE-133
GAS;INHALATION
XENON XE 133

>D>	AA	LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb	CTEC
>A>			20mCi/VIAL	N017284	002		Feb	CTEC
>D>		@ MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD
>A>			10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD
>D>		@	20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD
>A>			20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD

ZONISAMIDE
CAPSULE;ORAL
ZONEGRAN

>D>	AB	EISAI INC	25MG	N020789	003	Aug 22, 2003	Feb	CAHN
>D>	AB		50MG	N020789	002	Aug 22, 2003	Feb	CAHN
>D>	AB	+	100MG	N020789	001	Mar 27, 2000	Feb	CAHN
>A>	AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb	CAHN
>A>	AB		50MG	N020789	002	Aug 22, 2003	Feb	CAHN
>A>	AB	+	100MG	N020789	001	Mar 27, 2000	Feb	CAHN

ZONISAMIDE

AB		BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan	CAHN
AB			50MG	A077813	002	Aug 16, 2006	Jan	CAHN
AB			100MG	A077813	003	Aug 16, 2006	Jan	CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

		TABLET;ORAL						
		EXCEDRIN (MIGRAINE)						
>A>	+	GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802	001	Jan 14, 1998	Feb	CAHN
>D>	+	NOVARTIS	250MG;250MG;65MG	N020802	001	Jan 14, 1998	Feb	CAHN

CETIRIZINE HYDROCHLORIDE

		CAPSULE;ORAL						
		CETIRIZINE HYDROCHLORIDE ALLERGY						
		BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009	Jan	CAHN
	+		10MG	N022429	004	Jul 23, 2009	Jan	CAHN
		CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
		BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009	Jan	CAHN
	+		10MG	N022429	002	Jul 23, 2009	Jan	CAHN
		TABLET, CHEWABLE;ORAL						
		CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY						
>A>		NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016	Feb	NEWA
>A>			10MG	A206793	002	Mar 08, 2016	Feb	NEWA

CHLORPHENIRAMINE MALEATE

		CAPSULE, EXTENDED RELEASE;ORAL						
		CHLORPHENIRAMINE MALEATE						
>A>	@	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988	Feb	CAHN
>D>	@	SANDOZ	12MG	A070797	001	Aug 12, 1988	Feb	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

		CAPSULE;ORAL						
		IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE						
		BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan	CAHN

FLUTICASONE PROPIONATE

		SPRAY, METERED;NASAL						
>A>		FLUTICASONE PROPIONATE						
>A>		APOTEX TECHNOLOGIES	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Feb	NEWA

IBUPROFEN

		CAPSULE;ORAL						
		IBUPROFEN						
		BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan	CAHN
		MIDOL LIQUID GELS						
	+	BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002	Jan	CAHN

LEVONORGESTREL

		TABLET;ORAL						
		HER STYLE						
>A>		NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016	Feb	NEWA

LOPERAMIDE HYDROCHLORIDE

		CAPSULE;ORAL						
		LOPERAMIDE HYDROCHLORIDE						
		BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005	Jan	CAHN
	+		2MG	N021855	002	Aug 04, 2005	Jan	CAHN

NICOTINE POLACRILEX

		GUM, CHEWING;BUCCAL						
		NICOTINE POLACRILEX						
>A>		ACTAVIS LABS NY INC	EQ 4MG BASE	A204833	001	Feb 26, 2016	Feb	NEWA

OXYBUTYNIN

		FILM, EXTENDED RELEASE;TRANSDERMAL						
		OXYTROL FOR WOMEN						
	+	ALLERGAN SALES LLC	3.9MG/24HR	N202211	001	Jan 25, 2013	Jan	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 02 FEBRUARY 2016

NO FEBRUARY 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO FEBRUARY 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ							
N 205551 001	>A>	9242986	Oct 08, 2029	DS DP			
ACETYLCYSTEINE - CETYLEV							
N 207916 001		8747894	May 08, 2032	DP U-1373			
ACETYLCYSTEINE - CETYLEV							
N 207916 002		8747894	May 08, 2032	DP U-1373			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE							
N 207917 001		8809305	Dec 23, 2022	U-1078			
ALBUTEROL SULFATE - PROAIR RESPICLICK							
N 205636 001		8978966	Jan 13, 2032	DP			
		9216260	Jun 28, 2031	DP			
ALECTINIB HYDROCHLORIDE - ALECENSA							
N 208434 001						>A> ODE	Dec 11, 2022
AMPHETAMINE - ADZENYS XR-ODT							
N 204326 001	>A>	8709491	Jun 28, 2032	DP			
	>A>	8840924	Jun 05, 2026	DP			
	>A>	9017731	Jun 28, 2032	DP			
	>A>	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326 002	>A>	8709491	Jun 28, 2032	DP			
	>A>	8840924	Jun 05, 2026	DP			
	>A>	9017731	Jun 28, 2032	DP			
	>A>	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326 003	>A>	8709491	Jun 28, 2032	DP			
	>A>	8840924	Jun 05, 2026	DP			
	>A>	9017731	Jun 28, 2032	DP			
	>A>	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326 004	>A>	8709491	Jun 28, 2032	DP			
	>A>	8840924	Jun 05, 2026	DP			
	>A>	9017731	Jun 28, 2032	DP			
	>A>	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326 005	>A>	8709491	Jun 28, 2032	DP			
	>A>	8840924	Jun 05, 2026	DP			
	>A>	9017731	Jun 28, 2032	DP			
	>A>	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT							
N 204326 006	>A>	8709491	Jun 28, 2032	DP			
	>A>	8840924	Jun 05, 2026	DP			
	>A>	9017731	Jun 28, 2032	DP			
	>A>	9265737	Jun 28, 2032	DP			
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA							
N 202236 001	>A>	9259428	Jun 13, 2023	U-644			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR								
N 202331	001	>A>	9169238	Feb 04, 2030	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR								
N 202331	002	>A>	9169238	Feb 04, 2030	DP			
BALSALAZIDE DISODIUM - GIAZO								
N 022205	001		9192616	Aug 02, 2026	U-1229			
BENDAMUSTINE HYDROCHLORIDE - BENDEKA								
N 208194	001	>A>	9265831	Jan 28, 2031	DP			
BETAMETHASONE DIPROPIONATE - SERNIVO								
N 208079	001						>A> NDF	Feb 05, 2019
BIMATOPROST - LUMIGAN								
N 022184	001	>A>	9241918	Mar 16, 2025	DP U-1814			
BIMATOPROST - LATISSE								
N 022369	001		9216183	Jan 15, 2023	U-1487			
			9226931	Jan 15, 2023	U-1799			
BRIVARACETAM - BRIVIACT								
N 205836	001	>A>	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
		>A>	6911461	Feb 21, 2021	DS DP U-1815			
		>A>	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT								
N 205836	002	>A>	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
		>A>	6911461	Feb 21, 2021	DS DP U-1815			
		>A>	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT								
N 205836	003	>A>	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
		>A>	6911461	Feb 21, 2021	DS DP U-1815			
		>A>	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT								
N 205836	004	>A>	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
		>A>	6911461	Feb 21, 2021	DS DP U-1815			
		>A>	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT								
N 205836	005	>A>	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
		>A>	6911461	Feb 21, 2021	DS DP U-1815			
		>A>	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT								
N 205837	001	>A>	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
		>A>	6911461	Feb 21, 2021	DS DP U-1815			
		>A>	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT								
N 205838	001	>A>	6784197	Feb 21, 2021	DS DP U-1815		>A> NCE	Feb 18, 2021
		>A>	6911461	Feb 21, 2021	DS DP U-1815			
		>A>	8492416	Feb 21, 2021	U-1815			
BROMOCRIPTINE MESYLATE - CYCLOSET								
N 020866	001	>A>	9192576	Apr 30, 2032	DP U-976			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	001	>A>	9259421	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	002	>A>	9259421	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	003	>A>	9259421	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	004	>A>	9259421	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N 204242	005	>A>	9259421	Sep 18, 2032	DP			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE								
N 200063	001	>A>	9248123	Jan 13, 2032	U-1808			
CARFILZOMIB - KYPROLIS								
N 202714	001						I-722	Jan 21, 2019
							I-723	Jan 21, 2019
CEFIXIME - SUPRAX								
N 202091	001		9233112	Dec 14, 2028	DP U-1676			
CIPROFLOXACIN - OTIPRIO								
N 207986	001		9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA								
N 207561	001	>A>	7803788	Feb 02, 2022	U-257			
COBIMETINIB FUMARATE - COTELLIC								
N 206192	001						>A> ODE	Nov 10, 2022
CYCLOSPORINE - RESTASIS								
N 050790	001		9248191	Aug 27, 2024	U-1479			
CYSTEAMINE BITARTRATE - PROCYSBI								
N 203389	001		9233077	Jun 17, 2034	DP			
CYSTEAMINE BITARTRATE - PROCYSBI								
N 203389	002		9233077	Jun 17, 2034	DP			
DABRAFENIB MESYLATE - TAFINLAR								
N 202806	001	>A>	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
DABRAFENIB MESYLATE - TAFINLAR								
N 202806	002	>A>	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA								
N 206843	001						>A> D-161	Feb 05, 2019
							>A> D-162	Feb 05, 2019
							>A> I-726	Feb 05, 2019
							>A> I-727	Feb 05, 2019
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA								
N 206843	002						>A> D-161	Feb 05, 2019
							>A> D-162	Feb 05, 2019
							>A> I-726	Feb 05, 2019
							>A> I-727	Feb 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	002					>A> D-161	Feb 05, 2019
						>A> D-162	Feb 05, 2019
						>A> I-726	Feb 05, 2019
						>A> I-727	Feb 05, 2019
DALBAVANCIN HYDROCHLORIDE - DALVANCE							
N 021883	001					D-154	Jan 20, 2019
DAPSONE - ACZONE							
N 207154	001	>A> 5863560	Sep 11, 2016	DP		>A> NS	Feb 24, 2019
		>A> 6060085	Sep 11, 2016	U-124			
		>A> 6620435	Sep 11, 2016	DP			
		>A> 9161926	Nov 18, 2033	DP			
DEFERASIROX - JADENU							
N 206910	001					ODE	Jan 23, 2020
DEFERASIROX - JADENU							
N 206910	002					ODE	Jan 23, 2020
DEFERASIROX - JADENU							
N 206910	003					ODE	Jan 23, 2020
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST							
N 050818	001	>A> 8450287	Dec 19, 2027	DP			
DEXLANSOPRAZOLE - DEXILANT							
N 022287	001	>A> 9233103	Mar 05, 2032	U-1805			
		>A> 9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT							
N 022287	002	>A> 9233103	Mar 05, 2032	U-1805			
		>A> 9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT SOLUTAB							
N 208056	001	>A> 6238994	May 17, 2019	DP			
		>A> 6238994*PED	Nov 17, 2019				
		>A> 6462058	Jun 15, 2020	DS DP U-950			
		>A> 6462058	Jun 15, 2020	DS DP U-951			
		>A> 6462058*PED	Dec 15, 2020				
		>A> 6664276	Jan 30, 2023	DS DP U-950			
		>A> 6664276	Jan 30, 2023	DS DP U-951			
		>A> 6664276*PED	Jul 30, 2023				
		>A> 6939971	Jun 15, 2020	U-950			
		>A> 6939971	Jun 15, 2020	U-951			
		>A> 6939971*PED	Dec 15, 2020				
		>A> 7285668	Jun 15, 2020	DS			
		>A> 7285668*PED	Dec 15, 2020				
		>A> 7399485	May 26, 2018	DP			
		>A> 7399485*PED	Nov 26, 2018				
		>A> 7431942	May 17, 2019	DP			
		>A> 7431942*PED	Nov 17, 2019				
		>A> 7875292	May 17, 2019	DP			
		>A> 7875292*PED	Nov 17, 2019				
		>A> 8461187	Jan 17, 2026	DP			
		>A> 8461187*PED	Jul 17, 2026				
		>A> 8784885	Oct 15, 2023	DP			
		>A> 8784885*PED	Apr 15, 2024				
		>A> 8871273	Jan 11, 2028	DP			
		>A> 8871273*PED	Jul 11, 2028				
		>A> 9011926	Feb 24, 2026	DP			
		>A> 9145389	Jun 15, 2020	DS DP			
		>A> 9238029	Jan 17, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXLANSOPRAZOLE - DEXILANT SOLUTAB							
N 208056 001	>A>	9241910	Mar 10, 2029	DP			
DICLOFENAC SODIUM - PENNSAID							
N 204623 001		9220784	Oct 17, 2027	U-1488			
DOXEPIN HYDROCHLORIDE - SILENOR							
N 022036 001	>A>	9107898	May 01, 2028	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR							
N 022036 002	>A>	9107898	May 01, 2028	U-620			
DOXYCYCLINE - ORACEA							
N 050805 001		9241946	Apr 05, 2022	U-1063			
ELBASVIR; GRAZOPREVIR - ZEPATIER							
N 208261 001	>A>	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	>A>	8871759	May 04, 2031	DS DP U-1813			
EMPAGLIFLOZIN - JARDIANCE							
N 204629 001	>A>	8551957	Oct 19, 2029	DP U-1651			
EMPAGLIFLOZIN - JARDIANCE							
N 204629 002	>A>	8551957	Oct 19, 2029	DP U-1651			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073 001	>A>	7407955	May 02, 2025	DS DP			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073 002	>A>	7407955	May 02, 2025	DS DP			
EPINEPHRINE - AUVI-Q							
N 201739 001	>A>	9238108	Jan 22, 2027	DP			
EPINEPHRINE - AUVI-Q							
N 201739 002	>A>	9238108	Jan 22, 2027	DP			
EPINEPHRINE - ADRENALIN							
N 204200 001		9119876	Mar 13, 2035	DP			
ERIBULIN MESYLATE - HALAVEN							
N 201532 001	>A>	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	>A>	6469182	Jun 16, 2019	U-1812		>A> ODE	Jan 28, 2023
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511 001		9220698	Mar 10, 2031	U-1781			
EVEROLIMUS - AFINITOR							
N 022334 001	>A>	8410131	Nov 01, 2025	U-1368		>A> I-724	Feb 26, 2019
	>A>	8410131*PED	May 01, 2026				
EVEROLIMUS - AFINITOR							
N 022334 002	>A>	8410131	Nov 01, 2025	U-1368		>A> I-724	Feb 26, 2019
	>A>	8410131*PED	May 01, 2026				
EVEROLIMUS - AFINITOR							
N 022334 003	>A>	8410131	Nov 01, 2025	U-1368		>A> I-724	Feb 26, 2019
	>A>	8410131*PED	May 01, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR							
N 022334	004 >A>	8410131	Nov 01, 2025	U-1368		>A> I-724	Feb 26, 2019
	>A>	8410131*PED	May 01, 2026				
EXENATIDE SYNTHETIC - BYDUREON							
N 022200	001 >A>	9238076	Apr 15, 2024	DP U-412			
EXENATIDE SYNTHETIC - BYDUREON PEN							
N 022200	002 >A>	9238076	Apr 15, 2024	DP U-412			
FENTANYL - SUBSYS							
N 202788	001 >A>	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	002 >A>	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	003 >A>	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	004 >A>	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	005 >A>	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	006 >A>	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	007 >A>	9241935	Jan 25, 2027	DP			
FOSAPREPITANT DIMEGLUMINE - EMEND							
N 022023	002					>A> D-155	Feb 01, 2019
GLYCEROL PHENYLBUTYRATE - RAVICTI							
N 203284	001 >A>	5968979	Jul 28, 2018	DS DP U-1378			
	>A>	9254278	Mar 09, 2032	U-1816			
GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON							
N 207930	001 >A>	6878721	Feb 25, 2025	DS DP U-1773			
GRANISETRON - SANCUSO							
N 022198	001 >A>	7608282	Jan 22, 2025	DP U-1011			
HALOBETASOL PROPIONATE - ULTRAVATE							
N 208183	001					>A> NP	Nov 06, 2018
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	001 >A>	9265760	Jul 23, 2033	U-1810			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	002 >A>	9265760	Jul 23, 2033	U-1810			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	003 >A>	9265760	Jul 23, 2033	U-1810			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	004 >A>	9265760	Jul 23, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	005	>A> 9265760	Jul 23, 2033	U-1810			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	006	>A> 9265760	Jul 23, 2033	U-1810			
IMATINIB MESYLATE - IMATINIB MESYLATE							
A 078340	001					PC	Jul 30, 2016
IMATINIB MESYLATE - IMATINIB MESYLATE							
A 078340	002					PC	Jul 30, 2016
IMATINIB MESYLATE - GLEEVEC							
N 021335	001	>A> RE43932	Jul 16, 2018	DS DP			
		>A> RE43932*PED	Jan 16, 2019				
IMATINIB MESYLATE - GLEEVEC							
N 021335	002	>A> RE43932	Jul 16, 2018	DS DP			
		>A> RE43932*PED	Jan 16, 2019				
IMATINIB MESYLATE - GLEEVEC							
N 021588	001	>A> 7544799	Jul 16, 2018	DS DP	Y		
		>A> 7544799*PED	Jan 16, 2019				
		>A> RE43932	Jul 16, 2018	DS DP			
		>A> RE43932*PED	Jan 16, 2019				
IMATINIB MESYLATE - GLEEVEC							
N 021588	002	>A> 7544799	Jul 16, 2018	DS DP	Y		
		>A> 7544799*PED	Jan 16, 2019				
		>A> RE43932	Jul 16, 2018	DS DP			
		>A> RE43932*PED	Jan 16, 2019				
INDACATEROL MALEATE - ARCAPTA NEOHALER							
N 022383	001	>A> 6878721	Feb 25, 2025	DS DP U-1168			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR							
N 021081	002	9233211	Mar 02, 2024	DP			
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR							
N 206538	001	9233211	Mar 02, 2024	DP			
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR							
N 021629	003	9233211	Mar 02, 2024	DP			
INSULIN HUMAN - HUMULIN R							
N 018780	004	7291132	Aug 09, 2024	DP			
IRINOTECAN HYDROCHLORIDE - ONIVYDE							
N 207793	001					ODE	Oct 22, 2022
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	001	>A> 9216969	Nov 08, 2026	DS DP			
IVERMECTIN - SOOLANTRA							
N 206255	001	9233117	Mar 13, 2034	U-1631			
		9233118	Mar 13, 2034	U-1631			
IXAZOMIB CITRATE - NINLARO							
N 208462	001	9233115	Aug 12, 2024	U-1778		>A> ODE	Nov 20, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXAZOMIB CITRATE - NINLARO								
N 208462	002		9233115	Aug 12, 2024	U-1778		>A> ODE	Nov 20, 2022
IXAZOMIB CITRATE - NINLARO								
N 208462	003		9233115	Aug 12, 2024	U-1778		>A> ODE	Nov 20, 2022
KETOROLAC TROMETHAMINE - ACULAR LS								
N 021528	001	>A>	9216167	May 28, 2024	U-1800			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA								
N 205388	001	>A>	9278101	Jul 30, 2023	U-1518			
LEDIPASVIR; SOFOSBUVIR - HARVONI								
N 205834	001						>A> D-158	Feb 12, 2019
							>A> D-159	Feb 12, 2019
							>A> D-160	Feb 12, 2019
LESINURAD - ZURAMPIC								
N 207988	001		8003681	Aug 25, 2025	DS			
			8084483	Aug 17, 2029	U-1801			
			8283369	Nov 26, 2028	U-1802			
			8283369	Nov 26, 2028	U-1804			
			8357713	Nov 26, 2028	DP U-1801			
			8357713	Nov 26, 2028	DP U-1802			
			8357713	Nov 26, 2028	DP U-1803			
			8546436	Feb 29, 2032	DS DP			
			8546437	Apr 29, 2029	U-1803			
		>A>	9216179	Aug 02, 2030	U-1806			
LINAGLIPTIN - TRADJENTA								
N 201280	001	>A>	7407955	May 02, 2025	DS DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO								
N 201281	001	>A>	7407955	May 02, 2025	DS DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO								
N 201281	002	>A>	7407955	May 02, 2025	DS DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO								
N 201281	003	>A>	7407955	May 02, 2025	DS DP			
LIRAGLUTIDE RECOMBINANT - VICTOZA								
N 022341	001	>A>	9265893	Sep 23, 2032	DP			
LOMITAPIDE MESYLATE - JUXTAPID								
N 203858	001	>A>	5712279	Feb 21, 2020	DS DP U-1317			
		>A>	9265758	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID								
N 203858	002	>A>	5712279	Feb 21, 2020	DS DP U-1317			
		>A>	9265758	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID								
N 203858	003	>A>	5712279	Feb 21, 2020	DS DP U-1317			
		>A>	9265758	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID								
N 203858	004	>A>	5712279	Feb 21, 2020	DS DP U-1317			
		>A>	9265758	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 005	>A>	5712279	Feb 21, 2020	DS DP U-1317			
	>A>	9265758	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858 006	>A>	5712279	Feb 21, 2020	DS DP U-1317			
	>A>	9265758	Mar 07, 2025	U-1316			
LULICONAZOLE - LUZU							
N 204153 001		9199977	Sep 06, 2033	DS DP			
MACITENTAN - OPSUMIT							
N 204410 001	>A>	9265762	May 29, 2027	DP U-1820			
MENTHOL; METHYL SALICYLATE - SALONPAS							
N 022029 001	>A>	9233184	Aug 01, 2027	DP			
MENTHOL; METHYL SALICYLATE - SALONPAS							
N 022029 002	>A>	9233184	Aug 01, 2027	DP			
METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE							
A 091664 001						PC	Jul 30, 2016
METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE							
A 091664 002						PC	Jul 30, 2016
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET							
N 022044 001	>A>	7326708	Nov 24, 2026	DS DP U-802			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET							
N 022044 002	>A>	7326708	Nov 24, 2026	DS DP U-802			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR							
N 202270 001	>A>	7326708	Nov 24, 2026	DS DP U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR							
N 202270 002	>A>	7326708	Nov 24, 2026	DS DP U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR							
N 202270 003	>A>	7326708	Nov 24, 2026	DS DP U-1227			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 001	>A>	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 002	>A>	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 003	>A>	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 004	>A>	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 005	>A>	9248229	Mar 12, 2034	DP			
NALOXONE HYDROCHLORIDE - EVZIO							
N 205787 001		9238108	Jan 22, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	001	>A> 9205082	Dec 22, 2018	DP U-1556			
		>A> 9283216	May 10, 2022	DP U-1819			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	002	>A> 9205082	Dec 22, 2018	DP U-1556			
		>A> 9283216	May 10, 2022	DP U-1819			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	003	>A> 9205082	Dec 22, 2018	DP U-1556			
		>A> 9283216	May 10, 2022	DP U-1819			
OMEPRAZOLE MAGNESIUM - PRILOSEC							
N 022056	001	>A> 5900424	May 04, 2016	DS U-864			
		>A> 5900424	May 04, 2016	DS U-1817			
		>A> 6428810	Nov 03, 2019	DP U-864			
		>A> 6428810	Nov 03, 2019	DP U-1817			
OMEPRAZOLE MAGNESIUM - PRILOSEC							
N 022056	002	>A> 5900424	May 04, 2016	DS U-864			
		>A> 5900424	May 04, 2016	DS U-1817			
		>A> 6428810	Nov 03, 2019	DP U-864			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID							
N 021636	001	5840737	Jul 15, 2016	U-588			
		>A> 6489346	Jul 15, 2016	DP U-588	Y		
		>A> 6645988	Jul 15, 2016	DP	Y		
		>A> 6699885	Jul 15, 2016	U-588	Y		
		6780882	Jul 15, 2016	DS DP			
		7399772	Jul 15, 2016	U-588			
		>A> RE45198	Jul 15, 2016	U-588			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID							
N 021636	002	5840737	Jul 15, 2016	U-623			
		5840737	Jul 15, 2016	U-624			
		>A> 6489346	Jul 15, 2016	DP U-623	Y		
		>A> 6489346	Jul 15, 2016	DP U-624	Y		
		>A> 6645988	Jul 15, 2016	DP	Y		
		>A> 6699885	Jul 15, 2016	U-623	Y		
		>A> 6699885	Jul 15, 2016	U-624	Y		
		6780882	Jul 15, 2016	DS DP			
		7399772	Jul 15, 2016	U-623			
		7399772	Jul 15, 2016	U-624			
		>A> RE45198	Jul 15, 2016	U-623			
		>A> RE45198	Jul 15, 2016	U-624			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID							
N 021849	001	>A> 7399772	Jul 15, 2016	U-588			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID							
N 021849	002	7399772	Jul 15, 2016	U-623			
		7399772	Jul 15, 2016	U-624			
OSIMERTINIB MESYLATE - TAGRISSO							
N 208065	001					ODE	Nov 13, 2022
OSIMERTINIB MESYLATE - TAGRISSO							
N 208065	002					ODE	Nov 13, 2022
OSPEMIFENE - OSPHENA							
N 203505	001	9241915	Feb 13, 2024	U-1369			
		9241915	Feb 13, 2024	U-1370			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALBOCICLIB - IBRANCE							
N 207103	001	>A> 7456168	Jan 16, 2023	U-1658		>A> I-725	Feb 19, 2019
		>A> 7456168	Jan 16, 2023	U-1818			
PALBOCICLIB - IBRANCE							
N 207103	002	>A> 7456168	Jan 16, 2023	U-1658		>A> I-725	Feb 19, 2019
		>A> 7456168	Jan 16, 2023	U-1818			
PALBOCICLIB - IBRANCE							
N 207103	003	>A> 7456168	Jan 16, 2023	U-1658		>A> I-725	Feb 19, 2019
		>A> 7456168	Jan 16, 2023	U-1818			
PALONOSETRON HYDROCHLORIDE - ALOXI							
N 021372	001	>A> 9066980	Jan 30, 2024	DP U-528			
		>A> 9066980*PED	Jul 30, 2024				
		>A> 9125905	Jan 30, 2024	DP			
		>A> 9125905*PED	Jul 30, 2024				
		>A> 9173942	Jan 30, 2024	DP			
		>A> 9173942*PED	Jul 30, 2024				
PALONOSETRON HYDROCHLORIDE - ALOXI							
N 021372	002	>A> 9173942	Jan 30, 2024	DP			
		>A> 9173942*PED	Jul 30, 2024				
PROPOFOL - PROPOFOL							
A 205307	001					PC	Feb 24, 2016
RIVAROXABAN - XARELTO							
N 022406	001	>A> 7157456	Dec 11, 2020	DS DP U-1301			
		>A> 7157456	Dec 11, 2020	DS DP U-1302			
RIVAROXABAN - XARELTO							
N 022406	002	>A> 7157456	Dec 11, 2020	DS DP U-1301			
		>A> 7157456	Dec 11, 2020	DS DP U-1302			
RIVAROXABAN - XARELTO							
N 022406	003	>A> 7157456	Dec 11, 2020	DS DP U-1301			
		>A> 7157456	Dec 11, 2020	DS DP U-1302			
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	002	>A> 6858618	Dec 17, 2021	U-618			
		>A> 6858618	Dec 17, 2021	U-1032			
		>A> 6858618	Dec 17, 2021	U-1807			
		>A> 6858618*PED	Jun 17, 2022				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	003	>A> 6858618	Dec 17, 2021	U-618			
		>A> 6858618	Dec 17, 2021	U-1032			
		>A> 6858618	Dec 17, 2021	U-1807			
		>A> 6858618*PED	Jun 17, 2022				
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	004	>A> 6858618	Dec 17, 2021	U-618			
		>A> 6858618	Dec 17, 2021	U-1032			
		>A> 6858618	Dec 17, 2021	U-1807			
		>A> 6858618*PED	Jun 17, 2022				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN							
N 205065	001	9216178	Nov 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SAPROPTERIN DIHYDROCHLORIDE - KUVAN							
N 205065	002	7612073	Nov 17, 2024	U-1010			
		7612073*PED	May 17, 2025				
		9216178	Nov 01, 2032	DP			
		RE43797	Nov 17, 2024	U-1590			
		RE43797*PED	May 17, 2025				
SELEXIPAG - UPTRAVI							
N 207947	001	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP			
		9173881	Aug 12, 2029	U-1798			
SELEXIPAG - UPTRAVI							
N 207947	002	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP			
		9173881	Aug 12, 2029	U-1798			
SELEXIPAG - UPTRAVI							
N 207947	003	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP			
		9173881	Aug 12, 2029	U-1798			
SELEXIPAG - UPTRAVI							
N 207947	004	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP			
		9173881	Aug 12, 2029	U-1798			
SELEXIPAG - UPTRAVI							
N 207947	005	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP			
		9173881	Aug 12, 2029	U-1798			
SELEXIPAG - UPTRAVI							
N 207947	006	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP			
		9173881	Aug 12, 2029	U-1798			
SELEXIPAG - UPTRAVI							
N 207947	007	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP			
		9173881	Aug 12, 2029	U-1798			
SELEXIPAG - UPTRAVI							
N 207947	008	7205302	Apr 04, 2023	DS DP U-1797		>A> ODE	Dec 21, 2022
		8791122	Aug 01, 2030	DS DP			
		9173881	Aug 12, 2029	U-1798			
SEVELAMER CARBONATE - RENVELA							
N 022318	001	9095509	Dec 06, 2030	DP			
SEVELAMER CARBONATE - RENVELA							
N 022318	002	9095509	Dec 06, 2030	DP			
SIMEPREVIR SODIUM - OLYSIO							
N 205123	001					>A> M-171	Feb 26, 2019
SITAGLIPTIN PHOSPHATE - JANUVIA							
N 021995	001	>A> 7326708	Nov 24, 2026	DS DP U-802			
SITAGLIPTIN PHOSPHATE - JANUVIA							
N 021995	002	>A> 7326708	Nov 24, 2026	DS DP U-802			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SITAGLIPTIN PHOSPHATE - JANUVIA								
N 021995	003	>A>	7326708	Nov 24, 2026	DS DP		U-802	
SUGAMMADEX SODIUM - BRIDION								
N 022225	001		7265099	Aug 07, 2020			U-1795	
SUGAMMADEX SODIUM - BRIDION								
N 022225	002		7265099	Aug 07, 2020			U-1795	
SUMATRIPTAN SUCCINATE - ZECUITY								
N 202278	001	>A>	9272137	Sep 07, 2027	DP			
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL								
N 206099	001	>A>	6715485	Mar 03, 2020	DP			
		>A>	7975690	Aug 18, 2025	DP		U-1809	
		>A>	8047202	Jul 02, 2023	DP			
		>A>	8327844	Oct 03, 2023			U-1809	
		>A>	8550073	Oct 22, 2029	DP			
		>A>	8555877	Mar 03, 2020	DP			
		>A>	8590530	Sep 15, 2025	DP		U-1809	
		>A>	8875704	Apr 07, 2028	DP		U-1809	
		>A>	8899229	Aug 18, 2030	DP			
		>A>	8978647	Dec 06, 2030	DP			
		>A>	9108015	Sep 15, 2025	DP			
		>A>	9119932	Apr 23, 2024	DP			
TESTOSTERONE - ANDROGEL								
N 021015	001		9125816	Aug 30, 2020			U-490	
			9125816*PED	Mar 02, 2021				
			9132089	Aug 30, 2020			U-490	
			9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL								
N 021015	002		9125816	Aug 30, 2020			U-490	
			9125816*PED	Mar 02, 2021				
			9132089	Aug 30, 2020			U-490	
			9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL								
N 021015	003		9125816	Aug 30, 2020			U-490	
			9125816*PED	Mar 02, 2021				
			9132089	Aug 30, 2020			U-490	
			9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL								
N 022309	001		6503894	Aug 30, 2020			U-1103	
			6503894*PED	Mar 02, 2021				
			9125816	Aug 30, 2020			U-1103	
			9125816*PED	Mar 02, 2021				
			9132089	Aug 30, 2020			U-1103	
			9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL								
N 022309	002		6503894	Aug 30, 2020			U-1103	
			6503894*PED	Mar 02, 2021				
			9125816	Aug 30, 2020			U-1103	
			9125816*PED	Mar 02, 2021				
			9132089	Aug 30, 2020			U-1103	
			9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL								
N 022309	003		6503894	Aug 30, 2020			U-1103	
			6503894*PED	Mar 02, 2021				
			9125816	Aug 30, 2020			U-1103	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - ANDROGEL								
N 022309	003		9125816*PED	Mar 02, 2021				
			9132089	Aug 30, 2020	U-1103			
			9132089*PED	Mar 02, 2021				
TIGECYCLINE - TYGACIL								
N 021821	001	>A>	9254328	Mar 13, 2026	DP			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT								
N 020912	001	>A>	6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT								
N 020913	001	>A>	6770660	Jun 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT								
N 020913	002	>A>	6770660	Jun 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT								
N 020913	003	>A>	6770660	Jun 01, 2023	U-1444			
TOFACITINIB CITRATE - XELJANZ XR								
N 208246	001						>A> NCE	Nov 06, 2017
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST								
N 204114	001						M-170	Nov 20, 2018
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST								
N 204114	003						M-170	Nov 20, 2018
TREPROSTINIL DIOLAMINE - ORENITRAM								
N 203496	001	>A>	9278901	May 24, 2024	U-1475		>A> D-156	Jan 28, 2019
							>A> D-157	Jan 28, 2019
TREPROSTINIL DIOLAMINE - ORENITRAM								
N 203496	002	>A>	9278901	May 24, 2024	U-1475		>A> D-156	Jan 28, 2019
							>A> D-157	Jan 28, 2019
TREPROSTINIL DIOLAMINE - ORENITRAM								
N 203496	003	>A>	9278901	May 24, 2024	U-1475		>A> D-156	Jan 28, 2019
							>A> D-157	Jan 28, 2019
TREPROSTINIL DIOLAMINE - ORENITRAM								
N 203496	004	>A>	9278901	May 24, 2024	U-1475		>A> D-156	Jan 28, 2019
							>A> D-157	Jan 28, 2019
ULIPRISTAL ACETATE - ELLA								
N 022474	001	>A>	9283233	Apr 13, 2030	U-1821			
UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA								
N 205382	001						>A> M-172	Feb 24, 2019
URIDINE TRIACETATE - VISTOGARD								
N 208159	001						>A> ODE	Dec 11, 2022
VORTIOXETINE HYDROBROMIDE - BRINTELLIX								
N 204447	001		9227946	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX								
N 204447	002		9227946	Jun 15, 2027	U-1668			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 003	9227946	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 004	9227946	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm